Form 10-Q

Large accelerated filer

Accelerated filer

Non-accelerated filer

☐ (Do not check if a smaller reporting company)

Smaller reporting company

Emerging growth company

0001193125-17-167391.txt : 20170511 0001193125-17-167391.hdr.sgml : 20170511 20170511165430 ACCESSION NUMBER: 0001193125-17-167391 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 64 CONFORMED PERIOD OF REPORT: 20170331 FILED AS OF DATE: 20170511 DATE AS OF CHANGE: 20170511 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SUNLINK HEALTH SYSTEMS INC CENTRAL INDEX KEY: 0000096793 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-GENERAL MEDICAL & SURGICAL HOSPITALS, NEC [8062] IRS NUMBER: 310621189 STATE OF INCORPORATION: OH FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-12607 FILM NUMBER: 17835129 BUSINESS ADDRESS: STREET 1: 900 CIRCLE 75 PARKWAY STREET 2: SUITE 1120 CITY: ATLANTA STATE: GA ZIP: 30339 BUSINESS PHONE: 7709337000 MAIL ADDRESS: STREET 1: 900 CIRCLE 75 PARKWAY STREET 2: SUITE 1120 CITY: ATLANTA STATE: GA ZIP: 30339 FORMER COMPANY: FORMER CONFORMED NAME: KRUG INTERNATIONAL CORP DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: TECHNOLOGY INC DATE OF NAME CHANGE: 19860803 FORMER COMPANY: FORMER CONFORMED NAME: COMANCO INDUSTRIES INC DATE OF NAME CHANGE: 19710719 10-Q 1 d328223d10q.htm FORM 10-Q Form 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

FORM 10-Q

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2017

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number 1-12607

SUNLINK HEALTH SYSTEMS, INC.

(Exact name of registrant as specified in its charter)

Ohio

31-0621189

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification No.)

900 Circle 75 Parkway, Suite 1120, Atlanta, Georgia 30339

(Address of principal executive offices)

(Zip Code)

(770) 933-7000

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filings requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter during the preceding 12 months (of for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer, or a smaller reporting company. See definition of “large accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

The number of Common Shares, without par value, outstanding as of May 11, 2017 was 9,162,608.

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

SUNLINK HEALTH SYSTEMS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands)


	March 31,
	2017			June 30,
	(unaudited)			2016
ASSETS
Current Assets:
Cash and cash equivalents	$	11,237		$	3,261
Restricted cash		1,000			0
Receivables - net		6,300			6,166
Inventory		2,171			2,612
Deferred income tax asset		0			624
Current assets held for sale		0			2,461
Prepaid expense and other assets		2,784			2,768

Total current assets		23,492			17,892

Property, plant and equipment, at cost		31,669			33,914
Less accumulated depreciation		20,986			20,920

Property, plant and equipment - net		10,683			12,994

Noncurrent Assets:
Intangible assets - net		2,589			2,695
Goodwill		461			461
Deferred income tax asset		0			1,698
Noncurrent assets held for sale		0			7,633
Other noncurrent assets		908			732

Total noncurrent assets		3,958			13,219

TOTAL ASSETS	$	38,133		$	44,105

LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	1,851		$	3,391
Current maturities of long-term debt		503			7,473
Accrued payroll and related taxes		2,398			2,872
Due to third party payors		630			1,883
Current liabilities held for sale		0			2,745
Other accrued expenses		1,258			1,687

Total current liabilities		6,640			20,051
Long-Term Liabilities
Long-term debt, net of debt issuance costs		6,327			2,979
Noncurrent liability for professional liability risks		879			1,161
Other noncurrent liabilities		283			425

Total long-term liabilities		7,489			4,565

Commitment and Contingencies

Shareholders’ Equity
Preferred Shares, authorized and unissued, 2,000 shares		0			0
Common Shares, without par value:
Issued and outstanding, 9,163 shares at March 31, 2017 and 9,444 at June 30, 2016		4,581			4,722
Additional paid-in capital		13,099			13,539
Retained earnings		6,744			1,648
Accumulated other comprehensive loss		(420	)		(420	)

Total Shareholders’ Equity		24,004			19,489

TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY	$	38,133		$	44,105

SUNLINK HEALTH SYSTEMS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

AND COMPREHENSIVE EARNINGS (LOSS)

(In thousands, except per share amounts)

(unaudited)


	Three Months Ended						Nine Months Ended
	March 31,						March 31,
	2017			2016			2017			2016
Operating revenues (net of contractual allowances)	$	13,883		$	16,418		$	41,321		$	50,834
Less provision for bad debts of Healthcare Facilities Segment		184			213			321			1,461

Net revenues		13,699			16,205			41,000			49,373
Costs and Expenses
Cost of goods sold		5,523			5,614			15,592			15,582
Salaries, wages and benefits		5,872			7,675			17,476			23,918
Provision for bad debts of Specialty Pharmacy Segment		126			69			342			429
Supplies		455			647			1,373			2,486
Purchased services		692			761			2,113			2,510
Other operating expenses		1,194			1,958			4,015			6,125
Rent and lease expense		142			191			409			582
Depreciation and amortization		466			477			1,376			1,356

Operating Loss		(771	)		(1,187	)		(1,696	)		(3,615	)
Other Income, (Expense):
Gain on sale of assets		2			5			3,019			12
Loss on extinguishment of debt - net		0			0			(243	)		0
Interest expense - net		(129	)		(211	)		(507	)		(637	)

Earnings (Loss) from Continuing Operations before income taxes		(898	)		(1,393	)		573			(4,240	)
Income Tax Expense (Benefit)		(8	)		(1	)		(236	)		6,851

Earnings (Loss) from Continuing Operations		(890	)		(1,392	)		809			(11,091	)
Earnings (Loss) from Discontinued Operations, net of tax		(135	)		(443	)		4,287			(1,758	)

Net Earnings (Loss)		(1,025	)		(1,835	)		5,096			(12,849	)
Other comprehensive income		0			0			0			0

Comprehensive Earnings (Loss)	$	(1,025	)	$	(1,835	)	$	5,096		$	(12,849	)

Earnings (Loss) Per Share:
Continuing Operations:
Basic	$	(0.10	)	$	(0.15	)	$	0.09		$	(1.17	)

Diluted	$	(0.10	)	$	(0.15	)	$	0.09		$	(1.17	)

Discontinued Operations:
Basic	$	(0.01	)	$	(0.05	)	$	0.46		$	(0.19	)

Diluted	$	(0.01	)	$	(0.05	)	$	0.45		$	(0.19	)

Net Earnings (Loss):
Basic	$	(0.11	)	$	(0.19	)	$	0.54		$	(1.36	)

Diluted	$	(0.11	)	$	(0.19	)	$	0.54		$	(1.36	)

Weighted-Average Common Shares Outstanding:
Basic		9,334			9,443			9,408			9,443

Diluted		9,334			9,443			9,429			9,443

See notes to condensed consolidated financial statements.

SUNLINK HEALTH SYSTEMS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)


	Nine Months Ended March 31,
	2017			2016
Net Cash Used in Operating Activities	$	(4,999	)	$	(291	)

Cash Flows from Investing Activities:

Proceeds from sale of Chestatee		14,620			0
Proceeds from sale of medical office building and other assets		4,942			0
Expenditures for property, plant and equipment - continuing operations		(1,097	)		(1,127	)
Expenditures for property, plant and equipment - discontinued operations		0			(66	)

Net Cash Provided by (Used in) Investing Activities		18,465			(1,193	)

Cash Flows from Financing Activities:
Payments on long-term debt - continuing operation		(3,850	)		(601	)
Repurchase of common shares		(640	)		0
Deposit of restricted cash		(1,000	)		0

Net Cash Used in Financing Activities		(5,490	)		(601	)

Net increase (decrease) in Cash and Cash Equivalents		7,976			(2,085	)

Cash and Cash Equivalents Beginning of Period		3,261			5,974

Cash and Cash Equivalents End of Period	$	11,237		$	3,889

Supplement Disclosure of Cash Flow Information:

Cash Paid for:
Interest	$	458		$	579

Income taxes	$	141		$	78

SUNLINK HEALTH SYSTEMS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

THREE AND NINE MONTHS ENDED MARCH 31, 2017

(all dollar amounts in thousands except per share amounts)

(unaudited)

Note 1. –Basis of Presentation

The accompanying unaudited Condensed Consolidated Financial Statements as of March 31, 2017 and for the three and nine month periods ended March 31, 2017 and 2016 have been prepared in accordance with Rule 10-01 of Regulation S-X of the Securities and Exchange Commission (“SEC”) and, as such, do not include all information required by accounting principles generally accepted in the United States of America (“GAAP”). The condensed consolidated June 30, 2016 balance sheet included in this interim filing has been derived from the audited financial statements at that date but does not include all of the information and related notes required by GAAP for complete financial statements. These Condensed Consolidated Financial Statements should be read in conjunction with the audited consolidated financial statements included in the SunLink Health Systems, Inc. (“SunLink”, “we”, “our”, “ours”, “us” or the “Company”) Annual Report on Form 10-K for the fiscal year ended June 30, 2016, filed with the SEC on September 30, 2016. In the opinion of management, the Condensed Consolidated Financial Statements, which are unaudited, include all adjustments, consisting only of normal recurring adjustments, necessary to present fairly the financial position and results of operations for the periods indicated. The results of operations for the three and nine month periods ended March 31, 2017 are not necessarily indicative of the results that may be expected for the entire fiscal year or any other interim period.

Note 2. – Business Operations

Business Operations

SunLink owns businesses which are providers of healthcare services in certain non-urban markets in the United States. SunLink’s business is composed of the ownership of two business segments:

•

The Healthcare Facilities Segments, which is composed of:

•

A subsidiary which owns and operates an 84-licensed-bed, acute care hospital, located in Houston, Mississippi, which includes an 18-bed geriatric psychiatry unit (“GPU”) and a 66-bed nursing home.

•

A subsidiary which owns and operates a 100-bed nursing home located in Ellijay, Georgia. This subsidiary also owns a hospital building and leases a portion of that building to an unaffiliated healthcare provider.

•

A subsidiary which owns a medical office building and approximately two acres of unimproved land in Dahlonega, Georgia and a subsidiary which owns approximately 12 acres of unimproved land in Fulton, Missouri.

•

A subsidiary which owns a closed hospital building and a medical office building in Clanton, Alabama, a portion of which is currently rented to an unaffiliated healthcare provider.

•

The Specialty Pharmacy Segment, which is composed of four operational areas:

•

Pharmacy products and services which are conducted in rural markets at three locations in Louisiana;

•

Institutional pharmacy services consisting of the provision of specialty and non-specialty pharmaceutical and biological products to institutional clients or to patients in institutional settings, such as nursing homes, specialty hospitals, hospice, and correctional facilities;

•

Specialty pharmacy services; and

•

Durable medical equipment consisting primarily of products for nursing homes and patient-administered home care.

SunLink subsidiaries have conducted the healthcare facilities business since 2001 and the specialty pharmacy operations since 2008. Our Specialty Pharmacy Segment currently is operated through Carmichael’s Cashway Pharmacy, Inc. (“Carmichael”), a subsidiary of our SunLink ScriptsRx, LLC subsidiary.

The business strategy of SunLink is to focus its efforts on improving internal operations of the existing pharmacy business and healthcare facilities subsidiaries and on the sale or disposition of its subsidiaries’ underperforming assets. The Company considers the disposition of business segments, facilities and operations based on a variety of factors in addition to under-performance, including asset values, return on investments and competition from existing and potential competitors, capital improvement needs, the prevailing reimbursement environment under various Federal and state programs (e.g., Medicare and Medicaid) and by private payors, corporate strategy and other corporate objectives. The Company also is considering potential upgrades and improvements to certain of its healthcare facilities. The Company believes certain facilities in its Healthcare Facilities Segment as well as its Speciality Pharmacy Segment continue to under-perform, and the Company has engaged advisors to assist it in evaluating the possible sale of its specialty pharmacy business lines. The Company has used cash proceeds from recent dispositions of assets to pay off certain liabilities and to repurchase common shares in a tender offer completed in February 2017. The Company may use a portion of its existing cash, as well as any net proceeds from future dispositions, if any, to prepay debt, return capital to shareholders including through potential public or private purchases of share, make improvements to existing facilities, and for other general corporate purposes. There can be no assurance that any further dispositions, if any, will be authorized by the Company’s Board of Directors or, if authorized, that any such transactions will be completed or, if completed, will result in net cash proceeds to the Company on a before or after tax basis.

Throughout these notes to the consolidated financial statements, SunLink Health Systems, Inc., and its consolidated subsidiaries are referred to on a collective basis as “SunLink”, “we”, “our”, “ours”, “us” or the “Company.” This drafting style is not meant to indicate that SunLink Health Systems, Inc. or any particular subsidiary of SunLink Health Systems, Inc. owns or operates any asset, business, or property. The Trace Hospital, pharmacy operations and businesses described in this filing are owned and operated by distinct and indirect subsidiaries of SunLink Health System, Inc.

Note 3. – Discontinued Operations

All of the businesses discussed in the note below are reported as discontinued operations and the condensed consolidated financial statements for all prior periods have been adjusted to reflect this presentation.

Results for all of the businesses included in discontinued operations are presented in the following table:


	Three Months Ended						Nine Months Ended
	March 31,						March 31,
	2017			2016			2017			2016
Net Revenues:
Chestatee Hospital	$	—		$	3,771		$	2,369		$	11,357
Other Sold Hospitals		(68	)		17			(288	)		148

	$	(68	)	$	3,788		$	2,081		$	11,505

Earnings (Loss) before income taxes:
Chestatee Hospital	$	(104	)	$	(322	)	$	83		$	(1,432	)
Other Sold Hospitals		(69	)		(85	)		(304	)		(219	)
Life sciences and engineering		(37	)		(36	)		(112	)		(107	)
Gain on sale of Chestatee Hospital		0			0			7,270			0

Earnings (Loss) before income taxes		(210	)		(443	)		6,937			(1,758	)

Income tax expense (benefit)		(75	)		0			2,650			0

Earnings (Loss) from discontinued operations	$	(135	)	$	(443	)	$	4,287		$	(1,758	)

Chestatee Hospital—On August 19, 2016, Southern Health Corporation of Dahlonega, Inc., (“Chestatee”), a wholly owned subsidiary of the Company, sold substantially all of the assets and certain liabilities of Chestatee Regional Hospital in Dahlonega, Georgia through an asset purchase agreement for $15,000 subject to adjustment for the book value of certain assets and certain liabilities assumed at the sale date. The pre-tax gain on sale of $7,270 is subject to adjustment for various purchase price adjustments. Chestatee retained certain liabilities, including for employee related liabilities and certain Medicare and Medicaid liabilities, relating to the period it owned and operated the hospital. A portion of the net proceeds were used for the repayment of debt. The assets sold and liabilities assumed are shown as assets held for sale in our consolidated balances as of June 30, 2016.

Other Sold Hospitals – Subsidiaries of the Company have sold substantially all of the assets of three hospitals (“Other Sold Hospitals”) during the period July 2, 2012 to December 31, 2014. The loss before income taxes of the Other Sold Hospitals results primarily from negative prior year Medicare and Medicaid cost report settlements.

Life Sciences and Engineering Segment – SunLink retained a defined benefit retirement plan which covered substantially all of the employees of this segment when the segment was sold in fiscal 1998. Effective February 28, 1997, the plan was amended to freeze participant benefits and close the plan to new participants. Pension expense and related tax benefit or expense is reflected in the results of operations for this segment for the three and nine months ended March 31, 2017 and 2016.

The components of pension expense for the three and nine months ended March 31, 2017 and 2016, respectively, were as follows:


	Three Months Ended						Nine Months Ended
	March 31,						March 31,
	2017			2016			2017			2016
Interest Cost	$	13		$	16		$	39		$	48
Expected return on assets		(8	)		(8	)		(24	)		(24	)
Amortization of prior service cost		32			28			97			83

Net pension expense	$	37		$	36		$	112		$	107

SunLink contributed $105 to the plan in the nine months ended March 31, 2017 and expects to contribute an additional $35 during the last quarter of the fiscal year ending June 30, 2017.

Note 4. – Restricted Cash

Under an Fourth Amendment to the Trace RDA Loan (see Note 8. Long-Term Debt) a deposit of $1,000 into an interest bearing blocked account was made with the lender and certain financial covenants were modified. The deposit, which was made on January 13, 2017, will remain in the blocked account until compliance is achieved with respect to financial covenants in effect prior to the Amendment or until November 15, 2017, when the modified financial covenants will revert back to the pre-modification amounts. At March 31, 2017, Trace was in compliance with the modified covenants but not with the prior covenants.

Note 5. – Shareholders’ Equity

Common Share Purchase Tender Offer – SunLink purchased 280,800 of its common shares at a price of $1.50 per share as a result of a tender offer (the “Offer”) which expired February 24, 2017. The aggregate purchase price of the common shares, including expenses of the Offer was $640. The Offer was subject to a number of terms and conditions described in the Offer to Purchase distributed to shareholders.

Charter Amendments to Protect Net Operating Losses – On November 7, 2016, SunLink’s shareholders approved amendments to the Company’s article of incorporation to restrict certain transfers of common shares in order to protect future use of the Company’s federal and state income tax net operating losses. The amendments generally void transfers of shares that would result in the creation of a new 4.9% shareholder or result in an existing 4.9% shareholder acquiring additional shares. The purpose of the amendments is to assist the Company in protecting the value of its accumulated NOLs by limiting transfers of the Company’s common shares that could ultimately result in an “ownership change” under Section 382 of the Internal Revenue Code. The amendments to the Company’s articles of incorporation are designed to work in tandem with the Tax Benefits Preservation Rights Plan adopted by the company’s board of directors in September 2016.

Tax Benefits Protection Rights Plan – On September 29, 2016, SunLink entered into a Tax Benefits Preservation Rights Plan (the “Tax Benefits Protection Rights Plan”). Effective September 29, 2016, the Board declared a dividend in the form of one preferred stock purchase right for each of the Company’s issued and outstanding common shares. The purpose of the Tax Benefits Protection Rights Plan is to diminish the risk that the Company’s ability to use its net operating losses and certain other tax assets to reduce potential future federal income tax obligations would become subject to limitations by reason of the Company experiencing an “ownership change,” as defined in Section 382 of the Code.

Stock-Based Compensation

For the three months ended March 31, 2017 and 2016, the Company recognized $5 and $10, respectively, in stock based compensation for options issued to employees and directors of the Company. For the nine months ended March 31, 2017 and 2016, the Company recognized $59 and $49, respectively, in stock based compensation for options issued to employees and directors of the Company. The fair value of the share options granted was estimated using the Black-Scholes option pricing model. There were 72,000 and 30,000 share options granted under the 2011 Director Stock Option Plan during the nine months ended March 31, 2017 and 2016, respectively. There were 45,000 share options granted under the 2005 Equity Incentive Plan during the nine months ended March 31, 2016.

Note 6. – Revenue Recognition and Accounts Receivables

The Company’s subsidiaries recognize revenues in the period in which services are provided. Accounts receivable primarily consist of amounts due from third-party payors and patients. The Company’s subsidiaries’ ability to collect outstanding receivables is critical to their results of operations and cash flows. Amounts the Company’s subsidiaries receive for treatment of patients covered by governmental programs such as Medicare and Medicaid and other third-party payors such as health maintenance organizations (“HMOs”), preferred provider organizations (“PPOs”) and other private insurers are generally less than the Company’s subsidiaries’ established billing rates. Additionally, to provide for accounts receivable that could become uncollectible in the future an allowance for doubtful accounts is established to reduce the carrying value of such receivables to their estimated net realizable value. Accordingly, the revenues and accounts receivable reported in the accompanying unaudited condensed consolidated financial statements are recorded at the net amount expected to be received.

Revenues by payor were as follows for the three and nine months ended March 31, 2017 and 2016:


	Three Months Ended						Nine Months Ended
	March 31,						March 31,
	2017			2016			2017			2016
Healthcare Facilities Segment:
Medicare	$	2,079		$	3,199		$	6,447		$	9,202
Medicaid		2,285			3,006			7,185			9,235
Self-pay		86			107			356			1,231
Managed Care & Other Insurance		871			1,411			2,248			5,840
Other		92			35			374			102

Revenues before provision for doubtful accounts		5,413			7,758			16,610			25,610
Provision for doubtful accounts		(184	)		(213	)		(321	)		(1,461	)

Healthcare Facilities Segment Net Revenues		5,229			7,545			16,289			24,149
Pharmacy Segment Net Revenues		8,198			8,509			23,946			24,644
Other Revenues		272			151			765			580

Total Net Revenues	$	13,699		$	16,205		$	41,000		$	49,373

The net revenues of the Healthcare Facilities Segments included increases of $38 and $385 resulting from prior years’ Medicare cost report settlements for the three and nine months ended March 31, 2017 and increases (reductions) of $140 and ($662) resulting from prior years’ Medicare cost report settlements for the three and nine months ended March 31, 2016. The net revenues of the Pharmacy Segment are presented net of contractual adjustments. The provision for bad debts of the Pharmacy Segment is presented as a component of operating expenses in the Condensed Consolidated Statements of Operations and Comprehensive Loss.

Summary information for accounts receivable is as follows:


	March 31			June 30,
	2017			2016
Accounts receivable (net of contractual allowances)	$	7,010		$	7,157
Less allowance for doubtful accounts		(710	)		(991	)

Patient accounts receivable - net	$	6,300		$	6,166

The following is a summary of the activity in the allowance for doubtful accounts for the Healthcare Facilities Segment and the Pharmacy Segment for the three and nine months ended March 31, 2017 and 2016:


Three Months Ended March 31, 2017	Healthcare
	Facilities			Pharmacy			Total
Balance at January 1, 2017	$	332		$	400		$	732
Additions recognized as a reduction to revenues:
Continuing Operations		184			126			310
Discontinued Operations		(14	)		—			(14	)
Accounts written off, net of recoveries		(180	)		(138	)		(318	)

Balance at March 31, 2017	$	322		$	388		$	710


NIne Months Ended March 31, 2017	Healthcare
	Facilities			Pharmacy			Total
Balance at July 1, 2016	$	624		$	367		$	991
Additions recognized as a reduction to revenues:
Continuing Operations		321			342			663
Discontinued Operations		378			—			378
Accounts written off, net of recoveries		(1,001	)		(321	)		(1,322	)

Balance at March 31, 2017	$	322		$	388		$	710


Three Months Ended March 31, 2016	Healthcare
	Facilities			Pharmacy			Total
Balance at January 1, 2016	$	4,055		$	432		$	4,487
Additions recognized as a reduction to revenues:
Continuing Operations		213			69			282
Discontinued Operations		530			—			530
Accounts written off, net of recoveries		(1,698	)		(146	)		(1,844	)

Balance at March 31, 2016	$	3,100		$	355		$	3,455


Nine Months Ended March 31, 2016	Healthcare
	Facilities			Pharmacy			Total
Balance at July 1, 2015	$	4,962		$	385		$	5,347
Additions recognized as a reduction to revenues:
Continuing Operations		1,461			429			1,890
Discontinued Operations		2,116			—			2,116
Accounts written off, net of recoveries		(5,439	)		(459	)		(5,898	)

Balance at March 31, 2016	$	3,100		$	355		$	3,455

Note 7. - Goodwill and Intangible Assets

SunLink’s goodwill and intangible assets are composed of:


	March 31,		June 30,
	2017		2016
Pharmacy Segment Goodwill	$	461	$	461

Intangibles consist of the following, net of amortization:


	March 31,			June 30,
	2017			2016
Pharmacy Segment Intangibles
Trade Name (non-amortizing)		2,000			2,000
Customer Relationships		1,089			1,089
Medicare License		769			769

		3,858			3,858
Accumulated Amortization		(1,269	)		(1,163	)

Net Intangibles	$	2,589		$	2,695

Amortization expense was $35 and $35 for the three months ended March 31, 2017 and 2016, respectively. Amortization expense was $106 and $106 for the nine months ended March 31, 2017 and 2016, respectively.

Note 8. –Long-Term Debt

Long-term debt consisted of the following:


	March 31,			June 30,
	2017			2016
Trace RDA Loan	$	7,321		$	7,698
SHPP RDA Loan		0			1,950
Carmichael Notes		0			1,508
Capital lease obligations and other		17			32

Total		7,338			11,188
Less unamortized debt issuance costs		(508	)		(736	)
Less current maturities		(503	)		(7,473	)

	$	6,327		$	2,979

Trace RDA Loan and Trace Working Capital Loan—On July 11, 2012, Southern Health Corporation of Houston, Inc. (“Trace”) a wholly owned subsidiary of the Company, closed on a $9,975 Mortgage Loan Agreement (“Trace RDA Loan”) and a Working Capital Loan Agreement (which expired on July 2, 2016) with a bank, both dated as of July 5, 2012.

The Trace RDA Loan has a term of 15 years with monthly payments of principal and interest until repaid. The Trace RDA Loan bears a floating rate of interest equal to the greater of (i) the prime rate (as published in The Wall Street Journal) plus 1.5%, or (ii) 6% (6.0% at March 31, 2017). The Trace RDA Loan is collateralized by real estate and equipment of Trace in Houston, MS and is partially guaranteed under the U.S. Department of Agriculture, Rural Development Business and Industry Program.

The Company received a waiver of these non-compliances from the lender for both measurement dates and the Trace RDA Loan was amended by the Fourth Amendment to Loan Agreement and Waiver dated January 6, 2017. Under the Fourth Amendment, the debt service coverage, the fixed charge coverage and funded debt to EBITDA ratios were amended for periods ended December 31, 2016, March 31, 2017 and June 30, 2017 and an additional covenant was entered into requiring the deposit of $1,000 into a blocked interest bearing account with the lender. The deposit, which was made on January 13, 2017, will remain in the blocked account until Trace achieves compliance with financial covenants in effect prior to the Amendment or November 15, 2017, when the modified financial covenants will revert back to the pre-modification amounts. At March 31, 2017, Trace was in compliance with the modified covenants but not with the prior covenants. Indebtedness of $7,698 as of June 30, 2016 is presented in current liabilities in the condensed consolidated balance sheet as a result of the financial covenant non-compliance at that date. The ability of Trace to continue to make the required debt service payments under the Trace RDA Loan depends on, among other things, its ability to generate sufficient cash flows, including from operating activities. If Trace is unable to generate sufficient cash flow from operations to meet debt service payments on the Trace RDA Loan, including in the event the lender were to declare an event of default and accelerate the maturity of the indebtedness, such failure could have material adverse effects on the Company. The Trace RDA Loan is guaranteed by the Company and one subsidiary.

SHPP RDA Loan—On November 6, 2012, SunLink Healthcare Professional Property, LLC, (“SHPP”) a subsidiary of the Company, entered into and closed on a $2,100 term loan dated as of October 31, 2012 (the “SHPP RDA Loan”) with a bank. On December 16, 2016, SHPP repaid the remaining $1,933 outstanding principal balance of this loan when it sold the collateral for the SHPP RDA Loan, a medical office building located in Ellijay, Georgia. An early repayment penalty of $97 was paid at that date as required by loan terms and $192 of unamortized prepaid loan costs were expensed as of the sale date, both of which were reported as a loss on early repayment of debt of $289 for the nine months ended March 31, 2017.

Carmichael Notes—On April 22, 2008, SunLink Scripts Rx, LLC issued a $3,000 promissory note with an interest rate of 8% to the former owners of Carmichael as part of the acquisition purchase price (the “Carmichael Notes”). The Carmichael Notes, as amended, were payable in semi-annual installments of $185 of principal and plus accrued interest, with the remaining balance of $1,255 due October 22, 2017. Under an agreement dated September 9, 2016, between the Company and the Note holders, the Carmichael Notes balance of $1,508 was paid in full on September 9, 2016 and the accrued interest payable to that date of $46 was forgiven. A gain on retirement of debt of $46 for the nine months ended March 31, 2017 was reported for the accrued interest forgiveness.

ASU 2016-3, “Simplifying the Presentation of Debt Issuance Costs” —In April 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-3, “Simplifying the Presentation of Debt Issuance Costs” (“ASU 2016-3”). ASU 2016-3 requires debt issuance costs related to a recognized debt liability to be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts, rather than separately as an asset. The Company adopted the provisions of ASU 2016-3 on July 1, 2016 and retrospectively for all periods presented. The adoption of ASU 2016-3 had no impact on the Company’s results of operations or cash flows.

The following is a summary of the line items impact of the adoption of ASU 2016-3 in the Company’s June 30, 2016 accompanying condensed consolidated balance sheet:


	As		Adjustments			As
	Originally		for the Adoption			Currently
	Reported		of ASU 2015-3			Reported
Prepaid expense and other current assets	$	2,777	$	(9	)	$	2,768
Total current assets	$	17,901	$	(9	)	$	17,892
Other noncurrent assets	$	1,459	$	(727	)	$	732
Total noncurrent assets	$	13,946	$	(727	)	$	13,219
Total Assets	$	44,841	$	(736	)	$	44,105
Current maturities of long-term debt	$	8,012	$	(539	)	$	7,473
Total current liabilities	$	20,590	$	(539	)	$	20,051
Long-term debt	$	3,176	$	(197	)	$	2,979
Total long-term liabilities	$	4,762	$	(197	)	$	4,565
Total Liabilities and Shareholders’ Equity	$	44,841	$	(736	)	$	44,105

Note 9. – Income Taxes

Income tax benefit of $8 ($32 federal tax benefit and $24 state tax expense) and income tax benefit of $1 ($0 federal tax expense and $1 state tax benefit) was recorded for continuing operations for the three months ended March 31, 2017 and 2016, respectively. Income tax benefit of $236 ($221 federal tax benefit and $15 state tax benefit) and income tax expense of $6,851 ($6,210 federal tax expense and $641 state tax expense) was recorded for continuing operations for the nine months ended March 31, 2017 and 2016, respectively.

In accordance with the Financial Accounting Standards Board Accounting Standards Codification (‘ASC”) 740, we evaluate our deferred taxes quarterly to determine if adjustments to our valuation allowance are required based on the consideration of available positive and negative evidence using a “more likely than not” standard with respect to whether deferred tax assets will be realized. Our evaluation considers, among other factors, our historical operating results, our expectation of future results of operations, the duration of applicable statuary carryforward periods and conditions of the healthcare industry. The ultimate realization of our deferred tax assets depends primarily on our ability to generate future taxable income during the periods in which the related temporary differences in the financial basis and the tax basis of the assets become deductible. The value of our deferred tax assets will depend on applicable income tax rates.

At March 31, 2017, consistent with the above process, we evaluated the need for a valuation against our deferred tax assets and determined that it was more likely than not that none of our deferred tax assets would be realized. As a result, in accordance with ASC 740, we recognized a valuation allowance of $10,206 against the deferred tax asset so that there is no net long-term deferred income tax asset or liability at March 31, 2017. We conducted our evaluation by considering available positive and negative evidence to determine our ability to realize our deferred tax assets. In our evaluation, we gave more significant weight to evidence that was objective in nature as compared to subjective evidence. Also, more significant weight was given to evidence that directly related to our current financial performance as compared to less current evidence and future plans.

The principal negative evidence that led us to determine at March 31, 2017 that all the deferred tax assets should have full valuation allowances was the three-year cumulative pre-tax loss from continuing operations as well as the underlying negative business conditions for rural healthcare businesses in which our Healthcare Facilities Segment businesses operate.

For Federal income tax purposes, at March 31, 2017, the Company had approximately $11,100 of estimated net operating loss carry-forwards available for use in future years subject to the limitations of the provisions of Internal Revenue Code Section 382. The net operating loss carryforwards expire in 2024.

Note 10. – Commitments and Contingencies

Sale of Hospital Facilities — The Company has sold four hospital facilities since June 30, 2012 and in connection with the sales has retained certain assets and liabilities. – See Note 3 Discontinued Operations.

Contractual Obligations, Commitments and Contingencies

Contractual obligations, commitments and contingencies related to outstanding debt, non-cancelable operating leases and interest on outstanding debt from continuing operations at March 31, 2017 were as follows:


					Interest on
Payments	Long-Term		Operating		Outstanding
due in:	Debt		Leases		Debt
1 year	$	503	$	545	$	396
2 years		561		402		400
3 years		596		336		366
4 years		634		243		328
5+ years		5,044		59		803

	$	7,338	$	1,585	$	2,293

Note 11. - Related Party Transactions

A director of the Company and the Company’s former corporate secretary are members of two different law firms, each of which provides services to SunLink. The Company has expensed an aggregate of $109 and $71 for legal services to these law firms in the three months ended March 31, 2017 and 2016, respectively. The Company has expensed an aggregate of $481 and $204 for legal services to these law firms in the nine months ended March 31, 2017 and 2016, respectively. Included in the Company’s condensed consolidated balance sheets at March 31, 2017 and June 30, 2016 is $21 and $75, respectively, of amounts payable to these law firms.

Note 12. - Financial Information by Segment

Under ASC Topic No. 280, Segment Reporting, operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. Our chief operating decision-making group is composed of SunLink’s chief executive officer and other members of SunLink’s senior management. Our two reportable operating segments are Healthcare Facilities and Pharmacy.

changed to consistently apply the changed allocation method used in the current year. Segment information as of March 31, 2017 and 2016 and for the three and nine months then ended is as follows:


	Healthcare						Corporate
	Facilities			Pharmacy			and Other			Total
As of and for the three months ended March 31, 2017
Net revenues from external customers	$	5,229		$	8,198		$	272		$	13,699
Operating loss		(112	)		(324	)		(335	)		(771	)
Depreciation and amortization		150			289			27			466
Assets		12,458			11,519			14,156			38,133
Expenditures for property, plant and equipment		24			264			1			289

As of and for the three months ended March 31, 2016
Net revenues from external customers	$	7,545		$	8,509		$	151		$	16,205
Operating loss		(638	)		—			(549	)		(1,187	)
Depreciation and amortization		186			246			45			477
Assets		26,288			12,135			6,496			44,919
Expenditures for property, plant and equipment		8			292			2			302

As of and for the nine months ended March 31, 2017
Net revenues from external customers	$	16,289		$	23,946		$	765		$	41,000
Operating profit (loss)		443			(511	)		(1,628	)		(1,696	)
Depreciation and amortization		497			810			69			1,376
Assets		12,458			11,519			14,156			38,133
Expenditures for property, plant and equipment		246			739			112			1,097

As of and for the nine months ended March 31, 2016
Net revenues from external customers	$	24,149		$	24,644		$	580		$	49,373
Operating profit (loss)		(2,134	)		216			(1,697	)		(3,615	)
Depreciation and amortization		545			666			145			1,356
Assets		26,288			12,135			6,496			44,919
Expenditures for property, plant and equipment		93			1,031			3			1,127

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL

CONDITION AND RESULTS OF OPERATIONS

(Dollars in thousands, except per share and admissions data)

Forward-Looking Statements

This Quarterly Report and the documents that are incorporated by reference in this Quarterly Report contain certain forward-looking statements within the meaning of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts and may be identified by the use of words such as “may,” “believe,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan” or “continue.” These forward-looking statements are based on current plans and expectations and are subject to a number of risks, uncertainties and other factors which could significantly affect current plans and expectations and our future financial condition and results. These factors, which could cause actual results, performance and achievements to differ materially from those anticipated, include, but are not limited to:

General Business Conditions

•

general economic and business conditions in the U.S., both nationwide and in the states in which we operate;

•

increases in uninsured and/or underinsured patients due to unemployment or other conditions, higher deductibles and co-insurance, or other terms of health insurance coverage resulting in higher bad debt amounts;

•

the competitive nature of the U.S. community hospital, nursing home, and specialty pharmacy businesses;

•

demographic changes in areas where we operate;

•

the availability of cash or borrowings to fund working capital, renovations, replacements, expansions, and capital improvements at existing healthcare and specialty pharmacy facilities and for acquisitions and replacement of such facilities;

•

changes in accounting principles generally accepted in the U.S.; and

•

fluctuations in the market value of equity securities including SunLink common shares.

Operational Factors

•

ability or inability to operate profitably in one or more segments of the healthcare business;

•

the availability of, and our ability to attract and retain, sufficient qualified staff physicians, management, nurses, pharmacists, and staff personnel for our operations;

•

timeliness and amount of reimbursement payments received under government programs;

•

changes in interest rates under lending agreements and other indebtedness;

•

the ability or inability to refinance existing indebtedness and existing or potential defaults under existing indebtedness;

•

restrictions imposed by existing or future lending agreements or other indebtedness;

•

the cost and availability of insurance coverage including professional liability (e.g., medical malpractice) and general liability insurance;

•

the efforts of insurers, healthcare providers, and others to contain healthcare costs;

•

the impact on hospital services of the treatment of patients in lower acuity healthcare settings, whether with drug therapy or in alternative healthcare settings, such as surgery centers or urgent care centers;

•

changes in medical and other technology;

•

risks of changes in estimates of self-insurance claims and reserves;

•

changes in prices of materials and services utilized in our Healthcare Facilities and Specialty Pharmacy Segments;

•

changes in wages as a result of inflation or competition for physician, nursing, pharmacy, management and staff positions;

•

changes in the amount and risk of collectability of accounts receivable, including deductibles and co-pay amounts;

•

the functionality of or costs with respect to our information systems for our Healthcare Facilities and Specialty Pharmacy Segments and our corporate office, including both software and hardware;

•

the availability of and competition from alternative drugs or treatments to those provided by our Specialty Pharmacy Segment; and

•

the restrictions, processes, and conditions relating to our Pharmacy Segment imposed by pharmacy benefit providers, drug manufacturers, and distributors.

Liabilities, Claims, Obligations and Other Matters

•

claims under leases, guarantees, disposition agreements, and other obligations relating to discontinued operations, including claims from sold or leased facilities, retained liabilities or retained subsidiaries;

•

potential adverse consequences of known and unknown government investigations;

•

claims for product and environmental liabilities from continuing and discontinued operations;

•

professional, general, and other claims which may be asserted against us; and

•

natural disasters and weather-related events such as earthquakes, hurricanes, flooding, snow, ice and wind damage, and population evacuations affecting areas in which we operate.

Regulation and Governmental Activity

•

existing and proposed governmental budgetary constraints;

•

Federal and state insurance exchanges and their rules on reimbursement terms;

•

the decision by states in which we operate our remaining hospital (Mississippi) and two remaining nursing homes (Georgia and Mississippi) to not expand Medicaid;

•

the regulatory environment for our businesses, including state certificate of need laws and regulations, pharmacy licensing laws and regulations, rules and judicial cases relating thereto;

•

changes in the levels and terms of government (including Medicare, Medicaid and other programs) and private reimbursement for SunLink’s healthcare services including the payment arrangements and terms of managed care agreements; EHR reimbursement and indigent care reimbursements (Medicare Upper Payment Limit “UPL” and Disproportionate Share Hospital “DSH” adjustments);

•

changes in or failure to comply with Federal, state or local laws and regulations affecting our Healthcare Facilities and Specialty Pharmacy Segments; and

•

the possible enactment of additional Federal healthcare reform laws or reform laws in states where our subsidiaries operate hospital and pharmacy facilities (including Medicaid waivers, bundled payments, accountable care and similar organizations, competitive bidding and other reforms).

Dispositions, Acquisition and Renovation Related Matters

•

the ability to dispose of underperforming facilities and business segments;

•

the availability and terms of capital to fund acquisitions, improvements, renovations or replacement facilities; and

•

competition in the market for acquisitions of hospitals, nursing homes, pharmacy facilities, and healthcare businesses.

The foregoing are significant factors we think could cause our actual results to differ materially from expected results. However, there could be additional factors besides those listed herein that also could affect SunLink in an adverse manner.

You should read this Quarterly Report completely and with the understanding that actual future results may be materially different from what we expect. You are cautioned not to unduly rely on forward-looking statements when evaluating the information presented in this Quarterly Report or our other disclosures because current plans, anticipated actions, and future financial conditions and results may differ from those expressed in any forward-looking statements made by or on behalf of SunLink.

We have not undertaken any obligation to publicly update or revise any forward-looking statements. All of our forward-looking statements speak only as of the date of the document in which they are made or, if a date is specified, as of such date. We disclaim any obligation or undertaking to provide any updates or revisions to any forward-looking statement to reflect any change in our expectations or any changes in events, conditions, circumstances or information on which the forward-looking statement is based, except as required by applicable law. All subsequent written and oral forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the foregoing factors and the other risk factors set forth elsewhere in this report and in our Annual Report on Form 10-K.

Business Strategy: Operations, Dispositions and Acquisitions

The business strategy of SunLink is to focus its efforts on improving internal operations of the existing pharmacy business and healthcare facilities subsidiaries and on the sale or disposition of its subsidiaries’ underperforming assets. The Company considers the disposition of business segments, facilities and operations based on a variety of factors in addition to under-performance, including asset values, return on investments and competition from existing and potential competitors, capital improvement needs, the prevailing reimbursement environment under various Federal and state programs (e.g., Medicare and Medicaid) and by private payors, corporate strategy and other corporate objectives. The Company also is considering potential upgrades and improvements to certain of its healthcare facilities. The Company believes certain facilities in its Healthcare Facilities Segment as well as its Pharmacy Segment continue to under-perform, and the Company has engaged advisors to assist it in evaluating the possible sale of its specialty pharmacy business. The Company has used cash proceeds from recent dispositions of assets to pay off certain liabilities and to repurchase common shares in a tender offer completed in February 2017. The Company may use a portion of its existing cash, as well as any net proceeds from future dispositions, if any, to prepay debt, return capital to shareholders including through potential public or private purchases of share, make improvements to existing facilities, and for other general corporate purposes. There can be no assurance that any further dispositions, if any, will be authorized by the Company’s Board of Directors or, if authorized, that any such transactions will be completed or, if completed, will result in net cash proceeds to the Company on a before or after tax basis.

Critical Accounting Estimates

The preparation of financial statements in accordance with U.S. GAAP requires us to make estimates and assumptions that affect reported amounts and related disclosures. We consider an accounting estimate to be critical if:

•

it requires assumptions to be made that were uncertain at the time the estimate was made; and

•

changes in the estimate or different estimates that could have been made could have a material impact on our consolidated results of operations or financial condition.

Our critical accounting estimates are more fully described in our 2016 Annual Report on Form 10-K and continue to include the following areas:

•

Receivables – net and provision for doubtful accounts;

•

Revenue recognition / Net Patient Service Revenues;

•

Goodwill, intangible assets and accounting for business combinations;

•

Professional and general liability claims; and

•

Accounting for income taxes

Financial Summary

The results of continuing operations shown in the financial summary below are for our two business segments, Healthcare Facilities and Pharmacy.


	Three Months Ended									Nine Months Ended
				March 31,									March 31,
	2017			2016			% Change			2017			2016			% Change
Net Revenues - Healthcare Facilities	$	5,229		$	7,545			-30.7	%	$	16,289		$	24,149			-32.5	%
Net Revenues - Pharmacy		8,198			8,509			-3.7	%		23,946			24,644			-2.8	%
Other Revenues		272			151			80.1	%		765			580			31.9	%

Total Net Revenues		13,699			16,205			-15.5	%		41,000			49,373			-17.0	%
Costs and expenses		(14,470	)		(17,392	)		-16.8	%		(42,696	)		(52,988	)		-19.4	%

Operating loss		(771	)		(1,187	)		NA			(1,696	)		(3,615	)		NA
Interest expense - net		(129	)		(211	)		-38.9	%		(507	)		(637	)		-20.4	%
Loss on extinguishment of debt		0			0			NA			(243	)		0			NA
Gain on sale of assets		2			5			-60.0	%		3,019			12			NA

Earning (Loss) from continuing operations before income taxes	$	(898	)	$	(1,393	)		35.5	%	$	573		$	(4,240	)		NA

Healthcare Facilities Segment:
Hospital and Nursing Home Admissions		154			156			-1	%		400			679			-41	%
Nursing Home Patient Days		13,428			14,099			-5	%		41,989			43,091			-3	%

Results of Operations

Healthcare Facilities Segment Net Revenues

The following table sets forth the percentage of net patient revenues from major payors for the Healthcare Facilities Segment for the periods indicated:


	Three Months Ended						Nine Months Ended
	March 31,						March 31,
	2017			2016			2017			2016
Source:
Medicare		38.4	%		41.2	%		38.8	%		35.9	%
Medicaid		42.2	%		38.8	%		43.3	%		36.1	%
Managed Care Insurance & Other		17.8	%		18.6	%		15.7	%		23.2	%
Self-pay		1.6	%		1.4	%		2.2	%		4.8	%

		100.0	%		100.0	%		100.0	%		100.0	%

The Healthcare Facilities Segment in the current year is composed of two nursing homes, one hospital and two leased medical office buildings. During the three and nine months ended March 31, 2016, the segment operated a second hospital on the same site as one of the nursing homes, but closed this hospital in June 2016. Healthcare Facilities net revenues decreased $2,316 for the three months ended March 31, 2017 and $7,860 for the nine months ended March 31, 2017, compared to the prior year period primarily as a result of closing a hospital. Net revenues from all payer sources decreased compared to last year. The net revenues of the Healthcare Facilities Segments included increases of $38 and $385 resulting from prior years’ Medicare cost report settlements for the three and nine months ended March 31, 2017 and increases (reductions) of $140 and ($662) resulting from prior years’ Medicare cost report settlements for the three and nine months ended March 31, 2016.

Pharmacy Segment Net Revenues

Pharmacy Segment net revenues for the three months ended March 31, 2017 decreased $311, or 4%, from the three months ended March 31, 2016. The decrease was a result of a 10% decrease in Durable Medical Equipment (“DME”) and a 6% decrease in Retail Pharmacy net revenues partially offset by a 2% increase in Institutional Pharmacy net revenues. DME net revenues decreased primarily due to the negative effect of the expansion in January 2016 of Medicare Competitive Bidding in its service area. The average net revenue per DME sales order decreased 12% in the current year, primarily due to the Competitive Bidding expansion. The average net revenue per Retail Pharmacy sales order decreased 10% in the current year.

Pharmacy Segment net revenues for the nine months ended March 31, 2017 decreased $698, or 3%, from the nine months ended March 31, 2016. The decrease was a result of a 10% decrease in Durable Medical Equipment (“DME”) and a 5% decrease in Retail Pharmacy net revenues partially offset by 3% increase in Institutional Pharmacy net revenues. The average net revenue per DME sales order decreased 13% in the current year, primarily due to the Competitive Bidding expansion. The average net revenue per Retail Pharmacy sales order decreased 6% in the current year.

Healthcare Facilities Segment Cost and Expenses

Costs and expenses for our Healthcare Facilities Segment, including depreciation and amortization, were $5,341 and $8,183 for the three months ended March 31, 2017 and 2016, respectively. Costs and expenses for our Healthcare Facilities Segment, including depreciation and amortization, were $15,846 and $26,283 for the nine months ended March 31, 2017 and 2016, respectively.


	Cost and Expenses
	as a % of Net Revenues
	Three Months Ended						Nine Months Ended
	March 31,						March 31,
	2017			2016			2017			2016
Salaries, wages and benefits		68.1	%		70.1	%		64.4	%		69.8	%
Supplies		8.0	%		8.1	%		7.8	%		9.9	%
Purchased services		7.7	%		8.2	%		7.9	%		8.4	%
Other operating expenses		14.5	%		18.3	%		13.3	%		17.3	%
Rent and lease expense		0.9	%		1.2	%		0.8	%		1.1	%
Depreciation and amortization expense		2.9	%		2.5	%		3.0	%		2.3	%

All expense categories except depreciation and amortization decreased as a percentage of net revenues for the three months ended March 31, 2017. Depreciation and amortization expense decreased $37 this year. The $2,842 decrease in costs and expenses is due to the closure of one hospital included in the three months ended March 31, 2016. Similarly, all expense categories except depreciation and amortization decreased as a percentage of net revenues for the nine months ended March 31, 2017. Depreciation and amortization expense decreased $48 this year. The $10,437 decrease in costs and expenses is due to the closure of one hospital included in the nine months ended March 31, 2016.

Pharmacy Segment Cost and Expenses

Cost and expenses for our Pharmacy Segment, including depreciation and amortization, were $8,522 and $8,509 for the three months ended March 31, 2017 and 2016, respectively. Cost and expenses for our Pharmacy Segment, including depreciation and amortization, were $24,457 and $24,428 for the nine months ended March 31, 2017 and 2016, respectively.


	Cost and Expenses
	as a % of Net Revenues
	Three Months Ended						Nine Months Ended
	March 31,						March 31,
	2017			2016			2017			2016
Cost of goods sold		67.4	%		66.0	%		65.1	%		63.2	%
Salaries, wages and benefits		22.8	%		22.3	%		23.4	%		22.8	%
Provision for bad debts		1.5	%		0.8	%		1.4	%		1.7	%
Supplies		0.4	%		0.4	%		0.4	%		0.4	%
Purchased services		3.5	%		3.3	%		3.7	%		3.5	%
Other operating expenses		3.9	%		3.4	%		3.7	%		3.8	%
Rent and lease expense		1.0	%		0.8	%		1.0	%		1.0	%
Depreciation and amortization expense		3.5	%		2.9	%		3.4	%		2.7	%

Cost of goods sold as a percent of net revenues increased in the three and nine month periods ended March 31, 2017 as compared to the comparable periods of the prior year due to the increased of cost of certain generic drugs and changes in Institutional Pharmacy sales product mix for the current period.

Salaries, wages and benefits as a percent of net revenues increased in the three and nine month periods ended March 31, 2017 as compared to the comparable periods of the prior year due to the lower net revenues and an actual expense decrease of $32 in the current year three month results. Depreciation and amortization expense increased $44 and $145 in the current three and nine month periods, respectively, due to increased depreciation for capitalized rental DME and capitalized leasehold improvements.

Operating Profit and Loss

The Company reported an operating loss of $771 for the three months ended March 31, 2017 compared to an operating loss of $1,187 for the three months ended March 31, 2016. The operating loss for the three months ended March 31, 2017 decreased compared to the operating loss for the prior year’s three month period resulted from the closure of one hospital in June 2016 which was unprofitable. For the nine months ended March 31, 2017, an operating loss of $1,696 was reported compared to an operating loss of $3,615 for the same period last year. Positive adjustments for Medicare cost report adjustments of $385 for the nine months ended March 31, 2017 compared to negative adjustments of $662 for the nine months ended March 31, 2016 contributed to the reduction of the operating loss in the current year’s nine months results compared to the same period last year.

Gain on Sale of Assets

In December 2016, a subsidiary sold its medical office building complex, comprised of land and three buildings in Ellijay, GA (“Ellijay MOB”) for $4,900. A gain of $2,819 was reported on the sale. This property was the collateral for the SHPP RDA Loan, which was paid off at the closing of the sale.

Interest Expense

Interest expense was $129 and $211 for the three months ended March 31, 2017 and 2016, respectively, and $507 and $637 for the nine months ended March 31, 2017 and 2016, respectively. The decrease in interest expense resulted from lower debt outstanding as the SHPP RDA loan and Carmichael Notes were repaid earlier in the fiscal year.

Income Taxes

Earnings (Loss) from Continuing Operations before Income Tax

Loss from continuing operations before income tax were $898 for the three months ended March 31, 2017 compared to a loss from continuing operations before income tax of $1,393 for the three months ended March 31, 2016. The decreased loss in the three months ended March 31, 2017 when compared to the same quarter last year resulted from the $526 decrease in Healthcare Facilities Segment’s operating loss and lower interest expense.

Earnings from continuing operations before income tax was $573 for the nine months ended March 31, 2017 compared to a loss from continuing operations before income tax of $4,240 for the nine months ended March 31, 2016. The $2,819 gain on the sale of the Ellijay MOB resulted in earnings from continuing operations for the nine month period this year.

Earnings (Loss) After Taxes

Loss from continuing operations were $890 (or a loss of $0.10 per fully diluted share) for the three months ended March 31, 2017 compared to a loss from continuing operations of $1,392 (or a loss of $0.15 per fully diluted share) for the three months ended March 31, 2016. Earnings from continuing operations were $809 ($0.09 per fully diluted share) for the nine months ended March 31, 2017 compared to a loss from continuing operations of $11,091 (or a loss of $1.17 per fully diluted share) for the nine months ended March 31, 2016. The losses for the periods ended March 31, 2016 included higher income tax expense due to the need for full valuations for all deferred net tax assets as a result of continuing operating losses.

Loss from discontinued operations were $135 for the three months ended March 31, 2017, compared to a loss from discontinued operations of $443 for the three months ended March 31, 2016. Earnings from discontinued operations were $4,287 (including a gain on sale of Chestatee of $7,270 and income tax expense of $2,650) for the nine months ended March 31, 2017, compared to a loss from discontinued operations of $1,758 for the nine months ended March 31, 2016.

Net loss for the three months ended March 31, 2017 was $1,025 (or a loss of $0.11 fully diluted share) compared to net loss of $1,835 (a loss of $0.19 earnings per fully diluted share) for the three months ended March 31, 2016. Net income for the nine months ended March 31, 2017 was $5,096 (or $0.54 fully diluted share) compared to net loss of $12,849 (a loss of $1.36 earnings per fully diluted share) for the nine months ended March 31, 2016.

Adjusted earnings before income taxes, interest, depreciation and amortization

Earnings before income taxes, interest, depreciation and amortization (“EBITDA”) represent the sum of income before income taxes, interest, depreciation and amortization. We understand that certain industry analysts and investors generally consider EBITDA to be one measure of the liquidity of a company, and it is presented to assist analysts and investors in analyzing the ability of a company to generate cash, service debt and meet capital requirements. We believe increased EBITDA is an indicator of improved ability to service debt and to satisfy capital requirements. EBITDA, however, is not a measure of financial performance under accounting principles generally accepted in the United States of America and should not be considered an alternative to net income as a measure of operating performance or to cash liquidity. Because EBITDA is not a measure determined in accordance with accounting principles generally accepted in the United States of America and is thus susceptible to varying calculations, EBITDA, as presented, may not be comparable to other similarly titled measures of other corporations. Where we adjust EBITDA for non-cash charges, we refer to such measurement as “Adjusted EBITDA”, which we report on a Company wide basis. Non-cash adjustments in Adjusted EBITDA are not intended to be identified or characterized in any respect as “non-recurring, infrequent or unusual,” if we believe such charge is reasonably likely to recur within two years, or if there was a similar charge (or gain) within the prior two years. Where we report Adjusted EBITDA, we typically also report Healthcare Facilities Segment Adjusted EBITDA and Pharmacy Segment Adjusted EBITDA which is the EBITDA for the applicable segments without any allocation of corporate overhead, which we report as a separate line item, without gains on sales of businesses and without any allocation of the non-cash adjustments, which we also report as a separate line item in Adjusted EBITDA. Net cash used in operations for the three months ended March 31, 2017 and 2016, respectively, is shown below.


	Three Months Ended						Nine Months Ended
	March 31,						March 31,
	2017			2016			2017			2016
Healthcare Facilities Adjusted EBITDA	$	38		$	(452	)	$	940		$	(1,589	)
Pharmacy Adjusted EBITDA		(35	)		246			299			882
Corporate overhead costs		(308	)		(504	)		(1,559	)		(1,552	)
Taxes and interest expense		(121	)		(210	)		(271	)		(7,488	)
Other non-cash expenses and net change in operating assets and liabilities		(659	)		1,550			(4,408	)		9,456

Net cash used in operations	$	(1,085	)	$	630		$	(4,999	)	$	(291	)

Liquidity and Capital Resources

Overview

Our primary source of liquidity is cash on hand of $11,237 at March 31, 2017. Currently, the Company’s ability to raise capital (debt or equity) in the public or private markets on what it considers acceptable terms is uncertain. We nevertheless periodically seek options to obtain financing for the liquidity needs of the Company or individual subsidiaries. The Company and its subsidiaries currently are funding working capital needs primarily from cash on hand and from the sale of assets. See “Subsidiary Loans” below.

The Company believes its Healthcare Facilities Segment and its Pharmacy Segment business continue to underperform. The Company has incurred losses from continuing operations in nine of the last eleven fiscal quarters through the quarter ending March 31, 2017. See the “Business Strategy: Operations, Dispositions and Acquisitions” discussion earlier in this Item 2.

Subject to the risks and uncertainties discussed herein, we believe we have adequate financing and liquidity to support our current level of operations through the next twelve months.

Subsidiary Loans

Trace RDA Loan and Trace Working Capital Loan—On July 11, 2012, Southern Health Corporation of Houston, Inc. (“Trace”), a wholly owned subsidiary of the Company, closed on a $9,975 Mortgage Loan Agreement (“Trace RDA Loan”) and a Working Capital Loan Agreement (which expired on July 2, 2016) with a bank, both dated as of July 5, 2012.

The Trace RDA Loan contains various terms and conditions, including financial restrictions and limitations, and affirmative and negative covenants. The covenants include financial covenants measured on a quarterly basis which require Trace to comply with a ratio of current assets to current liabilities, debt service coverage, fixed charge ratio, and funded debt to EBITDA, all as defined in the Trace RDA Loan. At September 30, 2016 and June 30, 2016, Trace was not in compliance with the debt service coverage, fixed charge ratio and funded debt to EBITDA ratios. The Company received a waiver of these non-compliances from the lender for both measurement dates and the Trace RDA Loan was amended by the Fourth Amendment to Loan Agreement and Waiver dated January 6, 2017. Under the Fourth Amendment, the debt service coverage, the fixed charge coverage and funded debt to EBITDA ratios were amended for periods ended December 31, 2016, March 31, 2017 and June 30, 2017 and an additional covenant was entered into requiring the deposit of $1,000 into a blocked interest bearing account with the lender. The deposit, which was made on January 13, 2017, will remain in the blocked account until Trace achieves compliance with financial covenants in effect prior to the Amendment or November 15, 2017, when the modified financial covenants will revert back to the pre-modification amounts. At March 31, 2017, Trace was in compliance with the modified covenants but not the prior covenants. Indebtedness of $7,698 as of June 30, 2016 is presented in current liabilities in the condensed consolidated balance sheet as a result of the financial covenant non-compliance at that date. The ability of Trace to continue to make the required debt service payments under the Trace

RDA Loan depends on, among other things, its ability to generate sufficient cash flows, including from operating activities. If Trace is unable to generate sufficient cash flow from operations to meet debt service payments on the Trace RDA Loan, including in the event the lender were to declare an event of default and accelerate the maturity of the indebtedness, such failure could have material adverse effects on the Company. The Trace RDA Loan is guaranteed by the Company and one subsidiary.

SHPP RDA Loan—On November 6, 2012, SunLink Healthcare Professional Property, LLC, (“SHPP”), a subsidiary of the Company, entered into and closed on a $2,100 term loan dated as of October 31, 2012 (the “SHPP RDA Loan”) with a bank. On December 16, 2016, SHPP repaid the remaining $1,933 outstanding principal balance of this loan when it sold the collateral for the SHPP RDA Loan, a medical office building located in Ellijay, Georgia. An early repayment penalty of $97 was paid at that date as required by loan terms and $192 of unamortized prepaid loan costs were expensed as of the sale date, both of which were reported as a loss on early repayment of debt of $289 for the nine months ended March 31, 2017.

Contractual Obligations, Commitments and Contingencies


Payments due in:	Long-Term Debt		Operating Leases		Interest on Outstanding Debt
1 year	$	503	$	545	$	396
2 years		561		402		400
3 years		596		336		366
4 years		634		243		323
5+ years		5,044		59		808

	$	7,338	$	1,585	$	2,293

At March 31, 2017, we had outstanding long-term debt of $7,338 of which $7,321 was incurred under the Trace RDA Loan and $17 was related to other debt.

Discontinued Operations

the plan was amended to freeze participant benefits and close the plan to new participants. Pension expense and related tax benefit or expense is reflected in the results of operations for this segment for the three and nine months ended March 31, 2017 and 2016.

Related Party Transactions

ITEM 3.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We have not entered into any transactions using derivative financial instruments or derivative commodity instruments and believe that our exposure to market risk associated with other financial instruments (such as investments and borrowings) and interest rate risk is not material.

ITEM 4.

CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

As required by Rule 13a-15 and Rule 15d-15(e) under the Securities Exchange Act of 1934 (the “Exchange Act”), as of the end of the period covered by this report, we carried out an evaluation of the effectiveness of the design and operation of our Company’s disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) and the changes in our disclosure controls and procedures during the quarter. Under the direction of our principal executive officer and principal financial officer, we evaluated our disclosure controls and procedures and internal control over financial reporting and concluded that our disclosure controls and procedures were effective as of March 31, 2017.

Disclosure controls and procedures and other procedures are designed to ensure that information required to be disclosed in our reports or submitted under the Exchange Act, such as this Quarterly Report on Form 10-Q, is recorded, processed, summarized and reported within the time period specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports filed under the Exchange Act is accumulated and communicated to management, including our principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure.

Based on an evaluation of the effectiveness of disclosure controls and procedures performed in connection with the preparation of this Form 10-Q, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures were effective as of March 31, 2017.

Changes in Internal Control Over Financial Reporting

There were no changes during the quarter ended March 31, 2017 in our internal control over financial reporting that materially affected, or is likely to materially affect, our internal controls over financial reporting.

PART II. OTHER INFORMATION

Items required under Part II not specifically shown below are not applicable.

ITEM 1A.

RISK FACTORS

Risk Factors Relating to an Investment in SunLink

Information regarding risk factors appears in “MD&A – Forward-Looking Statements,” in Part I – Item 2 of this Form 10-Q and in “MD&A -Risks Factors Relating to an Investment in SunLink” in Part I – Item 1A of the Company’s Annual Report on Form 10-K for the year ended June 30, 2016. While we believe there have been no material changes from the risk factors previously disclosed in such Annual Report except as set forth herein, you should carefully consider, in addition to the other information set forth in this report, the risk factors discussed in our Annual Report which could materially affect our business, financial condition or future results. Such risk factors are expressly incorporated herein by reference. The risks described in our Annual Report are not the only risks facing our Company. In addition to risks and uncertainties inherent in forward-looking statements contained in this Report on Form 10-Q, additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and/or operating results. Whenever we refer to “SunLink,” “Company”, “we,” “our,” or “us” in this Item 1A, we mean SunLink Health Systems, Inc. and its subsidiaries, unless the context suggests otherwise.

ITEM 6.

EXHIBITS

Exhibits:



31.1		Chief Executive Officer’s Certification Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934.

31.2		Chief Financial Officer’s Certification Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934.

32.1		Chief Executive Officer’s Certification Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2		Chief Financial Officer’s Certification Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101		The following materials from the Company’s quarterly report on Form 10-Q for the three months ended March 31, 2017, formatted in XBRL (eXtensible Business Reporting Language): (i) Condensed Consolidated Balance Sheets as of March 31, 2017 (unaudited) and June 30, 2016, (ii) Condensed Consolidated Statements of Operations for the three and nine months ended March 31, 2017 and 2016 (unaudited), (iii) Condensed Consolidated Statements of Cash Flows for the three and nine months ended March 31, 2017 and 2016 (unaudited), and (iv) Notes to Condensed Consolidated Financial Statements (unaudited), tagged as blocks of text.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, SunLink Health Systems, Inc. has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


SunLink Health Systems, Inc.

By:		/s/ Mark J. Stockslager
		Mark J. Stockslager
		Chief Financial Officer

Dated: May 11, 2017

EX-31.1 2 d328223dex311.htm EX-31.1 EX-31.1

Exhibit 31.1

CERTIFICATION

I, Robert M. Thornton, Jr., the Chief Executive Officer of SunLink Health Systems, Inc. (the “registrant”), certify that:

(1) I have reviewed this quarterly report on Form 10-Q of the registrant for the period ended March 31, 2017 (the “report”);

(2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

(3) Based on my knowledge, the financial statements and other financial information included in this report fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

(4) The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of March 31, 2017 (the “Evaluation Date”), based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

(5) The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

EX-31.2 3 d328223dex312.htm EX-31.2 EX-31.2

Exhibit 31.2

CERTIFICATION

I, Mark J. Stockslager, the Chief Financial Officer of SunLink Health Systems, Inc. (the “registrant”), certify that:

(1) I have reviewed this quarterly report on Form 10-Q of the registrant for the period ended March 31, 2017 (the “report”);

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

May 11, 2017

/s/ Mark J. Stockslager

Mark J. Stockslager

SunLink Health Systems, Inc.

Chief Financial Officer

EX-32.1 4 d328223dex321.htm EX-32.1 EX-32.1

Exhibit 32.1

SUNLINK HEALTH SYSTEMS, INC.

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of SunLink Health Systems, Inc. (the “Company”) on Form 10-Q for the quarterly period ended March 31, 2017, as filed with the United States Securities and Exchange Commission on the date hereof (the “Report”), I, Robert M. Thornton, Jr., Chief Executive Officer of the Company, do hereby certify, pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


By:		/s/ Robert M. Thornton, Jr.
		Robert M. Thornton, Jr.
		Chief Executive Officer

May 11, 2017

EX-32.2 5 d328223dex322.htm EX-32.2 EX-32.2

Exhibit 32.2

SUNLINK HEALTH SYSTEMS, INC.

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of SunLink Health Systems, Inc. (the “Company”) on Form 10-Q for the quarterly period ended March 31, 2017, as filed with the United States Securities and Exchange Commission on the date hereof (the “Report”), I, Mark J. Stockslager, Chief Financial Officer of the Company, do hereby certify, pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


By:		/s/ Mark J. Stockslager
		Mark J. Stockslager
		Chief Financial Officer

May 11, 2017 LOGO

EX-101.INS 6 ssy-20170331.xml XBRL INSTANCE DOCUMENT

2100000

1255000

9162608 192000

0.08

3000000

4487000

432000

4055000

44919000

3455000

3889000

6496000

12135000

26288000

355000

3100000

732000

400000

332000

2398000

20986000

9163000

38133000

23492000

10206000

13099000

710000

17000

11237000

4581000

1851000

-420000

7010000

630000

11100000

2000000

6327000

7338000

503000

7489000

2589000

2171000

1258000

38133000

461000

283000

6640000

3958000

908000

10683000

31669000

24004000

6744000

2000000

2784000

1000000

508000

6300000

879000

14156000

11519000

12458000

0.060

7321000

1000000

0.06

561000

503000

7338000

5044000

596000

634000

400000

396000

2293000

803000

366000

328000

402000

545000

1585000

59000

336000

243000

1.50

2000000

1089000

769000

388000

1269000

2589000

461000

3858000

322000

21000

9975000

5347000

5974000

385000

4962000

2872000

20920000

9444000

44105000

17892000

13539000

991000

32000

3261000

1698000

4722000

3391000

624000

7633000

-420000

2461000

7157000

1883000

2000000

2979000

11188000

7473000

4565000

2695000

2612000

1687000

44105000

461000

425000

20051000

13219000

2745000

732000

12994000

33914000

19489000

1648000

2000000

2768000

736000

6166000

1161000

1508000

7698000

1950000

2000000

1089000

769000

367000

1163000

2695000

461000

3858000

624000

75000

44841000

17901000

3176000

8012000

4762000

44841000

20590000

13946000

1459000

2777000

-736000

-9000

-197000

-539000

-197000

-736000

-539000

-727000

-9000

7270000

15000000

0.049

1508000

46000

1933000

97000 SUNLINK HEALTH SYSTEMS INC

<div> Contractual obligations, commitments and contingencies related to outstanding debt, non-cancelable operating leases and interest on outstanding debt from continuing operations at March 31, 2017 were as follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="67%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center">Interest on</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom">Payments</td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center">Long-Term</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> Operating</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> Outstanding</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom" nowrap="nowrap"> due in: </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Debt</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Leases</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Debt</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> 1 year </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">503</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">545</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">396</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> 2 years </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">561</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">402</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">400</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> 3 years </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">596</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">336</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">366</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> 4 years </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">634</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">243</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">328</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> 5+ years </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,044</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">59</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">803</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,338</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,585</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,293</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

-221000

<div> Note 3. – Discontinued Operations All of the businesses discussed in the note below are reported as discontinued operations and the condensed consolidated financial statements for all prior periods have been adjusted to reflect this presentation.   Results for all of the businesses included in discontinued operations are presented in the following table:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="71%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center"> Three Months Ended</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center">Nine Months Ended</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center">March 31,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center">March 31,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Net Revenues: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Chestatee Hospital </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,771</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,369</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">11,357</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Other Sold Hospitals </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(68</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">17</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(288</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">148</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(68</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,788</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,081</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">11,505</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Earnings (Loss) before income taxes: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Chestatee Hospital </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(104</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(322</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">83</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(1,432</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Other Sold Hospitals </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(69</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(85</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(304</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(219</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Life sciences and engineering </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(37</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(36</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(112</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(107</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Gain on sale of Chestatee Hospital </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,270</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Earnings (Loss) before income taxes </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(210</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(443</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6,937</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,758</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Income tax expense (benefit) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(75</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,650</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Earnings (Loss) from discontinued operations </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(135</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(443</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,287</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(1,758</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> Chestatee Hospital—On August 19, 2016, Southern Health Corporation of Dahlonega, Inc., (“Chestatee”), a wholly owned subsidiary of the Company, sold substantially all of the assets and certain liabilities of Chestatee Regional Hospital in Dahlonega, Georgia through an asset purchase agreement for $15,000 subject to adjustment for the book value of certain assets and certain liabilities assumed at the sale date. The pre-tax gain on sale of $7,270 is subject to adjustment for various purchase price adjustments. Chestatee retained certain liabilities, including for employee related liabilities and certain Medicare and Medicaid liabilities, relating to the period it owned and operated the hospital. A portion of the net proceeds were used for the repayment of debt. The assets sold and liabilities assumed are shown as assets held for sale in our consolidated balances as of June 30, 2016. Other Sold Hospitals – Subsidiaries of the Company have sold substantially all of the assets of three hospitals (“Other Sold Hospitals”) during the period July 2, 2012 to December 31, 2014. The loss before income taxes of the Other Sold Hospitals results primarily from negative prior year Medicare and Medicaid cost report settlements. Life Sciences and Engineering Segment – SunLink retained a defined benefit retirement plan which covered substantially all of the employees of this segment when the segment was sold in fiscal 1998. Effective February 28, 1997, the plan was amended to freeze participant benefits and close the plan to new participants. Pension expense and related tax benefit or expense is reflected in the results of operations for this segment for the three and nine months ended March 31, 2017 and 2016. The components of pension expense for the three and nine months ended March 31, 2017 and 2016, respectively, were as follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="74%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center"> Three Months Ended</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center"> Nine Months Ended</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center">March 31,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center">March 31,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Interest Cost </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">13</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">16</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">39</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">48</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Expected return on assets </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(8</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(8</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(24</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(24</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Amortization of prior service cost </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">32</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">28</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">97</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">83</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Net pension expense </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">37</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">36</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">112</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">107</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> SunLink contributed $105 to the plan in the nine months ended March 31, 2017 and expects to contribute an additional $35 during the last quarter of the fiscal year ending June 30, 2017. </div>

10-Q 0000096793

<div> Note 7. - Goodwill and Intangible Assets SunLink’s goodwill and intangible assets are composed of:   <table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="80%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> March 31,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> June 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Pharmacy Segment Goodwill </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">461</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">461</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> Intangibles consist of the following, net of amortization:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="80%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> March 31,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> June 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Pharmacy Segment Intangibles </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Trade Name (non-amortizing) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,000</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,000</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Customer Relationships </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,089</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,089</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Medicare License </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">769</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">769</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,858</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,858</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Accumulated Amortization </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,269</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,163</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Net Intangibles </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,589</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,695</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> Amortization expense was $35 and $35 for the three months ended March 31, 2017 and 2016, respectively. Amortization expense was $106 and $106 for the nine months ended March 31, 2017 and 2016, respectively. </div>

2650000

2017-03-31

7976000

59000

2017 false --06-30

0.54

1376000

0.54

5096000

Smaller Reporting Company

106000

15592000

6937000

-15000

2113000

<div> Note 10. – Commitments and Contingencies Sale of Hospital Facilities — The Company has sold four hospital facilities since June 30, 2012 and in connection with the sales has retained certain assets and liabilities. – See Note 3 Discontinued Operations.   Contractual Obligations, Commitments and Contingencies Contractual obligations, commitments and contingencies related to outstanding debt, non-cancelable operating leases and interest on outstanding debt from continuing operations at March 31, 2017 were as follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="67%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center">Interest on</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom">Payments</td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center">Long-Term</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> Operating</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> Outstanding</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom" nowrap="nowrap"> due in: </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Debt</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Leases</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Debt</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> 1 year </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">503</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">545</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">396</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> 2 years </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">561</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">402</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">400</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> 3 years </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">596</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">336</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">366</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> 4 years </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">634</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">243</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">328</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> 5+ years </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,044</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">59</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">803</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,338</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,585</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,293</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

4287000

1322000

41000000

458000

409000

<div> Note 9. – Income Taxes Income tax benefit of $8 ($32 federal tax benefit and $24 state tax expense) and income tax benefit of $1 ($0 federal tax expense and $1 state tax benefit) was recorded for continuing operations for the three months ended March 31, 2017 and 2016, respectively. Income tax benefit of $236 ($221 federal tax benefit and $15 state tax benefit) and income tax expense of $6,851 ($6,210 federal tax expense and $641 state tax expense) was recorded for continuing operations for the nine months ended March 31, 2017 and 2016, respectively. In accordance with the Financial Accounting Standards Board Accounting Standards Codification (‘ASC”) 740, we evaluate our deferred taxes quarterly to determine if adjustments to our valuation allowance are required based on the consideration of available positive and negative evidence using a “more likely than not” standard with respect to whether deferred tax assets will be realized. Our evaluation considers, among other factors, our historical operating results, our expectation of future results of operations, the duration of applicable statuary carryforward periods and conditions of the healthcare industry. The ultimate realization of our deferred tax assets depends primarily on our ability to generate future taxable income during the periods in which the related temporary differences in the financial basis and the tax basis of the assets become deductible. The value of our deferred tax assets will depend on applicable income tax rates. At March 31, 2017, consistent with the above process, we evaluated the need for a valuation against our deferred tax assets and determined that it was more likely than not that none of our deferred tax assets would be realized. As a result, in accordance with ASC 740, we recognized a valuation allowance of $10,206 against the deferred tax asset so that there is no net long-term deferred income tax asset or liability at March 31, 2017. We conducted our evaluation by considering available positive and negative evidence to determine our ability to realize our deferred tax assets. In our evaluation, we gave more significant weight to evidence that was objective in nature as compared to subjective evidence. Also, more significant weight was given to evidence that directly related to our current financial performance as compared to less current evidence and future plans. The principal negative evidence that led us to determine at March 31, 2017 that all the deferred tax assets should have full valuation allowances was the three-year cumulative pre-tax loss from continuing operations as well as the underlying negative business conditions for rural healthcare businesses in which our Healthcare Facilities Segment businesses operate. For Federal income tax purposes, at March 31, 2017, the Company had approximately $11,100 of estimated net operating loss carry-forwards available for use in future years subject to the limitations of the provisions of Internal Revenue Code Section 382. The net operating loss carryforwards expire in 2024. </div>

17476000

5096000

4015000

342000

507000

0.46

321000

-4999000

-243000

-5490000

640000

0.45

14620000

3019000

-1696000

18465000

<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"> Note 8. –Long-Term Debt <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"> Long-term debt consisted of the following: <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">   <table style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="78%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> March 31,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> June 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Trace RDA Loan </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,321</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,698</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> SHPP RDA Loan </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,950</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Carmichael Notes </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,508</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Capital lease obligations and other </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">17</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">32</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,338</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">11,188</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Less unamortized debt issuance costs </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(508</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(736</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Less current maturities </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(503</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(7,473</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,327</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,979</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"> Trace RDA Loan and Trace Working Capital Loan—On July 11, 2012, Southern Health Corporation of Houston, Inc. (“Trace”) a wholly owned subsidiary of the Company, closed on a $9,975 Mortgage Loan Agreement (“Trace RDA Loan”) and a Working Capital Loan Agreement (which expired on July 2, 2016) with a bank, both dated as of July 5, 2012. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"> The Trace RDA Loan has a term of 15 years with monthly payments of principal and interest until repaid. The Trace RDA Loan bears a floating rate of interest equal to the greater of (i) the prime rate (as published in The Wall Street Journal) plus 1.5%, or (ii) 6% (6.0% at March 31, 2017). The Trace RDA Loan is collateralized by real estate and equipment of Trace in Houston, MS and is partially guaranteed under the U.S. Department of Agriculture, Rural Development Business and Industry Program. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"> The Trace RDA Loan contains various terms and conditions, including financial restrictions and limitations, and affirmative and negative covenants. The covenants include financial covenants measured on a quarterly basis which require Trace to comply with a ratio of current assets to current liabilities, debt service coverage, fixed charge ratio, and funded debt to EBITDA, all as defined in the Trace RDA Loan. At September 30, 2016 and June 30, 2016, Trace was not in compliance with the debt service coverage, fixed charge ratio and funded debt to EBITDA ratios. The Company received a waiver of these non-compliances from the lender for both measurement dates and the Trace RDA Loan was amended by the Fourth Amendment to Loan Agreement and Waiver dated January 6, 2017. Under the Fourth Amendment, the debt service coverage, the fixed charge coverage and funded debt to EBITDA ratios were amended for periods ended December 31, 2016, March 31, 2017 and June 30, 2017 and an additional covenant was entered into requiring the deposit of $1,000 into a blocked interest bearing account with the lender. The deposit, which was made on January 13, 2017, will remain in the blocked account until Trace achieves compliance with financial covenants in effect prior to the Amendment or November 15, 2017, when the modified financial covenants will revert back to the pre-modification amounts. At March 31, 2017, Trace was in compliance with the modified covenants but not with the prior covenants. Indebtedness of $7,698 as of June 30, 2016 is presented in current liabilities in the condensed consolidated balance sheet as a result of the financial covenant non-compliance at that date. The ability of Trace to continue to make the required debt service payments under the Trace RDA Loan depends on, among other things, its ability to generate sufficient cash flows, including from operating activities. If Trace is unable to generate sufficient cash flow from operations to meet debt service payments on the Trace RDA Loan, including in the event the lender were to declare an event of default and accelerate the maturity of the indebtedness, such failure could have material adverse effects on the Company. The Trace RDA Loan is guaranteed by the Company and one subsidiary. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"> SHPP RDA Loan—On November 6, 2012, SunLink Healthcare Professional Property, LLC, (“SHPP”) a subsidiary of the Company, entered into and closed on a $2,100 term loan dated as of October 31, 2012 (the “SHPP RDA Loan”) with a bank. On December 16, 2016, SHPP repaid the remaining $1,933 outstanding principal balance of this loan when it sold the collateral for the SHPP RDA Loan, a medical office building located in Ellijay, Georgia. An early repayment penalty of $97 was paid at that date as required by loan terms and $192 of unamortized prepaid loan costs were expensed as of the sale date, both of which were reported as a loss on early repayment of debt of $289 for the nine months ended March 31, 2017. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"> Carmichael Notes—On April 22, 2008, SunLink Scripts Rx, LLC issued a $3,000 promissory note with an interest rate of 8% to the former owners of Carmichael as part of the acquisition purchase price (the “Carmichael Notes”). The Carmichael Notes, as amended, were payable in semi-annual installments of $185 of principal and plus accrued interest, with the remaining balance of $1,255 due October 22, 2017. Under an agreement dated September 9, 2016, between the Company and the Note holders, the Carmichael Notes balance of $1,508 was paid in full on September 9, 2016 and the accrued interest payable to that date of $46 was forgiven. A gain on retirement of debt of $46 for the nine months ended March 31, 2017 was reported for the accrued interest forgiveness. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"> ASU 2016-3, “Simplifying the Presentation of Debt Issuance Costs” —In April 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-3, “Simplifying the Presentation of Debt Issuance Costs” (“ASU 2016-3”). ASU 2016-3 requires debt issuance costs related to a recognized debt liability to be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts, rather than separately as an asset. The Company adopted the provisions of ASU 2016-3 on July 1, 2016 and retrospectively for all periods presented. The adoption of ASU 2016-3 had no impact on the Company’s results of operations or cash flows. <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">   <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"> The following is a summary of the line items impact of the adoption of ASU 2016-3 in the Company’s June 30, 2016 accompanying condensed consolidated balance sheet: <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">   <table style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="65%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center">As</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> Adjustments</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center">As</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> Originally</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> for the Adoption</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> Currently</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Reported</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">of ASU 2015-3</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Reported</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Prepaid expense and other current assets </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,777</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(9</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,768</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Total current assets </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">17,901</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(9</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">17,892</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Other noncurrent assets </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,459</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(727</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">732</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Total noncurrent assets </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">13,946</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(727</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">13,219</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Total Assets </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">44,841</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(736</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">44,105</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Current maturities of long-term debt </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">8,012</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(539</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,473</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Total current liabilities </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">20,590</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(539</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">20,051</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Long-term debt </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,176</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(197</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,979</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Total long-term liabilities </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,762</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(197</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,565</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Total Liabilities and Shareholders’ Equity </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">44,841</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(736</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">44,105</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> </table> </div>

141000

809000

0.09

<div> Note 1. –Basis of Presentation The accompanying unaudited Condensed Consolidated Financial Statements as of March 31, 2017 and for the three and nine month periods ended March 31, 2017 and 2016 have been prepared in accordance with Rule 10-01 of Regulation S-X of the Securities and Exchange Commission (“SEC”) and, as such, do not include all information required by accounting principles generally accepted in the United States of America (“GAAP”). The condensed consolidated June 30, 2016 balance sheet included in this interim filing has been derived from the audited financial statements at that date but does not include all of the information and related notes required by GAAP for complete financial statements. These Condensed Consolidated Financial Statements should be read in conjunction with the audited consolidated financial statements included in the SunLink Health Systems, Inc. (“SunLink”, “we”, “our”, “ours”, “us” or the “Company”) Annual Report on Form 10-K for the fiscal year ended June 30, 2016, filed with the SEC on September 30, 2016. In the opinion of management, the Condensed Consolidated Financial Statements, which are unaudited, include all adjustments, consisting only of normal recurring adjustments, necessary to present fairly the financial position and results of operations for the periods indicated. The results of operations for the three and nine month periods ended March 31, 2017 are not necessarily indicative of the results that may be expected for the entire fiscal year or any other interim period. </div>

573000

-236000

1097000

0.09

4942000

<div> The following is a summary of the line items impact of the adoption of ASU 2016-3 in the Company’s June 30, 2016 accompanying condensed consolidated balance sheet:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="65%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center">As</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> Adjustments</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center">As</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> Originally</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> for the Adoption</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> Currently</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Reported</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">of ASU 2015-3</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Reported</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Prepaid expense and other current assets </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,777</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(9</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,768</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Total current assets </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">17,901</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(9</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">17,892</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Other noncurrent assets </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,459</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(727</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">732</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Total noncurrent assets </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">13,946</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(727</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">13,219</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Total Assets </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">44,841</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(736</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">44,105</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Current maturities of long-term debt </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">8,012</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(539</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,473</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Total current liabilities </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">20,590</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(539</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">20,051</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Long-term debt </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,176</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(197</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,979</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Total long-term liabilities </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,762</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(197</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,565</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Total Liabilities and Shareholders’ Equity </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">44,841</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(736</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">44,105</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> </table> </div>

9429000

1373000

<div> SunLink’s goodwill and intangible assets are composed of:   <table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="80%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> March 31,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> June 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Pharmacy Segment Goodwill </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">461</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">461</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> Note 4. – Restricted Cash Under an Fourth Amendment to the Trace RDA Loan (see Note 8. Long-Term Debt) a deposit of $1,000 into an interest bearing blocked account was made with the lender and certain financial covenants were modified. The deposit, which was made on January 13, 2017, will remain in the blocked account until compliance is achieved with respect to financial covenants in effect prior to the Amendment or until November 15, 2017, when the modified financial covenants will revert back to the pre-modification amounts. At March 31, 2017, Trace was in compliance with the modified covenants but not with the prior covenants. </div>

9408000

SSY

<div> Results for all of the businesses included in discontinued operations are presented in the following table:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="71%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center"> Three Months Ended</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center">Nine Months Ended</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">March 31,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">March 31,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Net Revenues: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Chestatee Hospital </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,771</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,369</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">11,357</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Other Sold Hospitals </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(68</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">17</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(288</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">148</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(68</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,788</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,081</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">11,505</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Earnings (Loss) before income taxes: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Chestatee Hospital </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(104</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(322</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">83</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(1,432</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Other Sold Hospitals </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(69</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(85</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(304</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(219</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Life sciences and engineering </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(37</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(36</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(112</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(107</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Gain on sale of Chestatee Hospital </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,270</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Earnings (Loss) before income taxes </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(210</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(443</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6,937</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,758</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Income tax expense (benefit) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(75</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,650</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Earnings (Loss) from discontinued operations </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(135</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(443</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,287</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(1,758</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> Summary information for accounts receivable is as follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="80%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> March 31</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> June 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Accounts receivable (net of contractual allowances) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,010</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,157</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Less allowance for doubtful accounts </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(710</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(991</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Patient accounts receivable - net </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,300</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,166</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"> Note 12. - Financial Information by Segment <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"> Under ASC Topic No. 280, Segment Reporting, operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. Our chief operating decision-making group is composed of SunLink’s chief executive officer and other members of SunLink’s senior management. Our two reportable operating segments are Healthcare Facilities and Pharmacy. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"> We evaluate performance of our operating segments based on revenue and operating profit (loss). At the beginning of the current fiscal year, the Company modified the approach to certain assets, and expense allocations to calculate segment assets, operating profit and depreciation and amortization. All prior year amounts have been changed to consistently apply the changed allocation method used in the current year. Segment information as of March 31, 2017 and 2016 and for the three and nine months then ended is as follows: <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">   <table style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="66%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> Healthcare</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> Corporate</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Facilities</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Pharmacy</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">and Other</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> As of and for the three months ended March 31, 2017 </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Net revenues from external customers </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,229</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">8,198</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">272</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">13,699</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Operating loss </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(112</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(324</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(335</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(771</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Depreciation and amortization </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">150</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">289</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">27</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">466</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Assets </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">12,458</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">11,519</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">14,156</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">38,133</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Expenditures for property, plant and equipment </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">24</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">264</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">289</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> As of and for the three months ended March 31, 2016 </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Net revenues from external customers </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,545</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">8,509</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">151</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">16,205</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Operating loss </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(638</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(549</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,187</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Depreciation and amortization </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">186</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">246</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">45</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">477</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Assets </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">26,288</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">12,135</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6,496</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">44,919</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Expenditures for property, plant and equipment </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">292</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">302</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> As of and for the nine months ended March 31, 2017 </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Net revenues from external customers </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">16,289</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">23,946</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">765</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">41,000</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Operating profit (loss) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">443</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(511</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,628</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,696</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Depreciation and amortization </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">497</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">810</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">69</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,376</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Assets </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">12,458</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">11,519</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">14,156</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">38,133</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Expenditures for property, plant and equipment </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">246</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">739</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">112</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,097</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> As of and for the nine months ended March 31, 2016 </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Net revenues from external customers </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">24,149</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">24,644</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">580</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">49,373</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Operating profit (loss) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(2,134</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">216</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,697</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(3,615</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Depreciation and amortization </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">545</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">666</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">145</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,356</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Assets </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">26,288</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">12,135</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6,496</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">44,919</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Expenditures for property, plant and equipment </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">93</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,031</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,127</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> </table> </div>

<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"> We evaluate performance of our operating segments based on revenue and operating profit (loss). At the beginning of the current fiscal year, the Company modified the approach to certain assets, and expense allocations to calculate segment assets, operating profit and depreciation and amortization. All prior year amounts have been changed to consistently apply the changed allocation method used in the current year. Segment information as of March 31, 2017 and 2016 and for the three and nine months then ended is as follows: <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">   <table style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="66%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> Healthcare</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> Corporate</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Facilities</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Pharmacy</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">and Other</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> As of and for the three months ended March 31, 2017 </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Net revenues from external customers </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,229</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">8,198</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">272</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">13,699</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Operating loss </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(112</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(324</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(335</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(771</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Depreciation and amortization </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">150</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">289</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">27</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">466</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Assets </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">12,458</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">11,519</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">14,156</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">38,133</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Expenditures for property, plant and equipment </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">24</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">264</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">289</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> As of and for the three months ended March 31, 2016 </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Net revenues from external customers </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,545</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">8,509</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">151</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">16,205</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Operating loss </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(638</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(549</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,187</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Depreciation and amortization </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">186</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">246</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">45</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">477</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Assets </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">26,288</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">12,135</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6,496</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">44,919</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Expenditures for property, plant and equipment </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">292</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">302</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> As of and for the nine months ended March 31, 2017 </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Net revenues from external customers </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">16,289</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">23,946</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">765</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">41,000</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Operating profit (loss) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">443</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(511</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,628</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,696</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Depreciation and amortization </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">497</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">810</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">69</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,376</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Assets </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">12,458</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">11,519</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">14,156</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">38,133</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Expenditures for property, plant and equipment </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">246</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">739</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">112</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,097</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> As of and for the nine months ended March 31, 2016 </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Net revenues from external customers </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">24,149</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">24,644</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">580</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">49,373</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Operating profit (loss) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(2,134</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">216</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,697</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(3,615</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Depreciation and amortization </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">545</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">666</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">145</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,356</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Assets </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">26,288</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">12,135</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6,496</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">44,919</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Expenditures for property, plant and equipment </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">93</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,031</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,127</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> </table> </div>

<div> Revenues by payor were as follows for the three and nine months ended March 31, 2017 and 2016:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="68%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center">Three Months Ended</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center">Nine Months Ended</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">March 31,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">March 31,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Healthcare Facilities Segment: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Medicare </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,079</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,199</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,447</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">9,202</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Medicaid </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,285</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,006</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,185</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">9,235</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Self-pay </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">86</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">107</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">356</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,231</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Managed Care & Other Insurance </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">871</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,411</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,248</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,840</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Other </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">92</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">35</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">374</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">102</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Revenues before provision for doubtful accounts </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,413</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,758</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">16,610</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">25,610</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Provision for doubtful accounts </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(184</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(213</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(321</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,461</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Healthcare Facilities Segment Net Revenues </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,229</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,545</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">16,289</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">24,149</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Pharmacy Segment Net Revenues </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8,198</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8,509</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">23,946</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">24,644</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Other Revenues </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">272</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">151</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">765</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">580</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Total Net Revenues </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">13,699</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">16,205</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">41,000</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">49,373</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

3850000

<div> Note 11. - Related Party Transactions A director of the Company and the Company’s former corporate secretary are members of two different law firms, each of which provides services to SunLink. The Company has expensed an aggregate of $109 and $71 for legal services to these law firms in the three months ended March 31, 2017 and 2016, respectively. The Company has expensed an aggregate of $481 and $204 for legal services to these law firms in the nine months ended March 31, 2017 and 2016, respectively. Included in the Company’s condensed consolidated balance sheets at March 31, 2017 and June 30, 2016 is $21 and $75, respectively, of amounts payable to these law firms. </div>

41321000 1097000 <div> The components of pension expense for the three and nine months ended March 31, 2017 and 2016, respectively, were as follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="74%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center"> Three Months Ended</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center"> Nine Months Ended</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">March 31,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">March 31,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Interest Cost </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">13</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">16</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">39</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">48</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Expected return on assets </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(8</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(8</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(24</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(24</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Amortization of prior service cost </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">32</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">28</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">97</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">83</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Net pension expense </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">37</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">36</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">112</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">107</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div> <div> Intangibles consist of the following, net of amortization:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="80%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> March 31,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> June 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Pharmacy Segment Intangibles </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Trade Name (non-amortizing) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,000</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,000</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Customer Relationships </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,089</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,089</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Medicare License </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">769</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">769</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,858</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,858</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Accumulated Amortization </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,269</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,163</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Net Intangibles </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,589</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,695</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div> 0 <div> Long-term debt consisted of the following:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="78%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> March 31,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> June 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Trace RDA Loan </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,321</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,698</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> SHPP RDA Loan </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,950</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Carmichael Notes </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,508</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Capital lease obligations and other </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">17</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">32</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,338</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">11,188</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Less unamortized debt issuance costs </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(508</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(736</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Less current maturities </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(503</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(7,473</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,327</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,979</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div> <div> The following is a summary of the activity in the allowance for doubtful accounts for the Healthcare Facilities Segment and the Pharmacy Segment for the three and nine months ended March 31, 2017 and 2016:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="72%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom">Three Months Ended March 31, 2017</td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> Healthcare</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Facilities</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Pharmacy</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Balance at January 1, 2017 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">332</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">400</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">732</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Additions recognized as a reduction to revenues: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Continuing Operations </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">184</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">126</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">310</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Discontinued Operations </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(14</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(14</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Accounts written off, net of recoveries </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(180</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(138</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(318</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Balance at March 31, 2017 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">322</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">388</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">710</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="16"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom">NIne Months Ended March 31, 2017</td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> Healthcare</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Facilities</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Pharmacy</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Balance at July 1, 2016 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">624</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">367</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">991</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Additions recognized as a reduction to revenues: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Continuing Operations </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">321</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">342</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">663</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Discontinued Operations </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">378</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">378</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Accounts written off, net of recoveries </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,001</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(321</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,322</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Balance at March 31, 2017 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">322</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">388</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">710</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="16"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom">Three Months Ended March 31, 2016</td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> Healthcare</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Facilities</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Pharmacy</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Balance at January 1, 2016 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,055</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">432</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,487</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Additions recognized as a reduction to revenues: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Continuing Operations </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">213</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">69</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">282</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Discontinued Operations </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">530</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">530</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Accounts written off, net of recoveries </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,698</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(146</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,844</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Balance at March 31, 2016 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,100</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">355</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,455</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="16"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom">Nine Months Ended March 31, 2016</td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> Healthcare</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Facilities</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Pharmacy</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Balance at July 1, 2015 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,962</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">385</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,347</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Additions recognized as a reduction to revenues: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Continuing Operations </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,461</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">429</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,890</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Discontinued Operations </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,116</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,116</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Accounts written off, net of recoveries </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(5,439</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(459</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(5,898</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Balance at March 31, 2016 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,100</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">355</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,455</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> </tr> </table> </div> <div> Note 6. – Revenue Recognition and Accounts Receivables The Company’s subsidiaries recognize revenues in the period in which services are provided. Accounts receivable primarily consist of amounts due from third-party payors and patients. The Company’s subsidiaries’ ability to collect outstanding receivables is critical to their results of operations and cash flows. Amounts the Company’s subsidiaries receive for treatment of patients covered by governmental programs such as Medicare and Medicaid and other third-party payors such as health maintenance organizations (“HMOs”), preferred provider organizations (“PPOs”) and other private insurers are generally less than the Company’s subsidiaries’ established billing rates. Additionally, to provide for accounts receivable that could become uncollectible in the future an allowance for doubtful accounts is established to reduce the carrying value of such receivables to their estimated net realizable value. Accordingly, the revenues and accounts receivable reported in the accompanying unaudited condensed consolidated financial statements are recorded at the net amount expected to be received.   Revenues by payor were as follows for the three and nine months ended March 31, 2017 and 2016:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="68%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center">Three Months Ended</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center">Nine Months Ended</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center">March 31,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center">March 31,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Healthcare Facilities Segment: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Medicare </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,079</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,199</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,447</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">9,202</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Medicaid </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,285</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,006</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,185</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">9,235</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Self-pay </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">86</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">107</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">356</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,231</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Managed Care & Other Insurance </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">871</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,411</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,248</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,840</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Other </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">92</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">35</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">374</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">102</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Revenues before provision for doubtful accounts </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,413</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,758</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">16,610</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">25,610</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Provision for doubtful accounts </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(184</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(213</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(321</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,461</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Healthcare Facilities Segment Net Revenues </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,229</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,545</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">16,289</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">24,149</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Pharmacy Segment Net Revenues </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8,198</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8,509</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">23,946</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">24,644</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Other Revenues </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">272</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">151</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">765</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">580</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Total Net Revenues </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">13,699</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">16,205</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">41,000</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">49,373</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> The net revenues of the Healthcare Facilities Segments included increases of $38 and $385 resulting from prior years’ Medicare cost report settlements for the three and nine months ended March 31, 2017 and increases (reductions) of $140 and ($662) resulting from prior years’ Medicare cost report settlements for the three and nine months ended March 31, 2016. The net revenues of the Pharmacy Segment are presented net of contractual adjustments. The provision for bad debts of the Pharmacy Segment is presented as a component of operating expenses in the Condensed Consolidated Statements of Operations and Comprehensive Loss. Summary information for accounts receivable is as follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="80%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> March 31</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> June 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Accounts receivable (net of contractual allowances) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,010</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,157</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Less allowance for doubtful accounts </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(710</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(991</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Patient accounts receivable - net </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,300</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,166</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table>   The following is a summary of the activity in the allowance for doubtful accounts for the Healthcare Facilities Segment and the Pharmacy Segment for the three and nine months ended March 31, 2017 and 2016:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="72%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom">Three Months Ended March 31, 2017</td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> Healthcare</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Facilities</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Pharmacy</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Balance at January 1, 2017 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">332</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">400</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">732</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Additions recognized as a reduction to revenues: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Continuing Operations </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">184</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">126</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">310</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Discontinued Operations </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(14</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(14</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Accounts written off, net of recoveries </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(180</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(138</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(318</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Balance at March 31, 2017 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">322</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">388</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">710</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="16"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom">NIne Months Ended March 31, 2017</td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> Healthcare</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Facilities</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Pharmacy</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Balance at July 1, 2016 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">624</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">367</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">991</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Additions recognized as a reduction to revenues: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Continuing Operations </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">321</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">342</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">663</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Discontinued Operations </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">378</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">378</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Accounts written off, net of recoveries </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,001</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(321</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,322</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Balance at March 31, 2017 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">322</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">388</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">710</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="16"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom">Three Months Ended March 31, 2016</td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> Healthcare</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Facilities</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Pharmacy</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Balance at January 1, 2016 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,055</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">432</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,487</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Additions recognized as a reduction to revenues: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Continuing Operations </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">213</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">69</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">282</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Discontinued Operations </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">530</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">530</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Accounts written off, net of recoveries </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,698</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(146</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,844</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Balance at March 31, 2016 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,100</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">355</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,455</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="16"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom">Nine Months Ended March 31, 2016</td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> Healthcare</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Facilities</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Pharmacy</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Balance at July 1, 2015 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,962</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">385</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,347</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Additions recognized as a reduction to revenues: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Continuing Operations </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,461</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">429</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,890</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Discontinued Operations </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,116</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,116</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Accounts written off, net of recoveries </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(5,439</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(459</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(5,898</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Balance at March 31, 2016 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,100</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">355</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,455</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> </tr> </table> </div> 2024 4 385000 1000000

69000

765000

-1628000

112000

810000

23946000

-511000

739000

497000

16289000

443000

246000

2081000

-112000

7270000

83000

2369000

-304000

-288000

185000

2008-04-22

2017-10-22

46000

0.015

P15Y

Under the Fourth Amendment, the debt service coverage, the fixed charge coverage and funded debt to EBITDA ratios were amended for periods ended December 31, 2016, March 31, 2017 and June 30, 2017 and an additional covenant was entered into requiring the deposit of $1,000 into a blocked interest bearing account with the lender. The deposit, which was made on January 13, 2017, will remain in the blocked account until Trace achieves compliance with financial covenants in effect prior to the Amendment or November 15, 2017

2016-07-02

2012-07-05

Trace RDA Loan bears a floating rate of interest equal to the greater of (i) the prime rate (as published in The Wall Street Journal) plus 1.5%, or (ii) 6%

2012-07-05

-289000

2012-10-31

280800

72000

640000

2017-02-24 84 18 66 356000 2248000 7185000 374000 6447000

97000

39000

24000

35000

105000

112000

663000

342000

321000

378000

4 3

321000

23946000

1001000

16289000

321000

16610000 100 2 12 765000

481000

6210000

-2085000

49000

-1.36

1356000

-1.36

-12849000

106000

15582000

-1758000

641000

2510000

-1758000

5898000

49373000

579000

582000

23918000

-12849000

6125000

429000

637000

-0.19

1461000

-291000

-601000

-0.19

12000

-3615000

-1193000

78000

-11091000

-1.17

-4240000

6851000

1127000

-1.17

9443000

2486000

9443000

601000

50834000 1127000 66000 -662000 0

145000

580000

-1697000

3000

666000

24644000

216000

1031000

545000

24149000

-2134000

93000

11505000

-107000

-1432000

11357000

-219000

148000

30000

45000

1231000 5840000 9235000 102000 9202000

83000

48000

24000

107000

1890000

429000

1461000

2116000

459000

24644000

5439000

24149000

1461000

25610000 580000

204000

-32000

-75000

5000

-0.11

466000

-0.11

-1025000

35000

5523000

-210000

24000

692000

-135000

318000

13699000

142000

5872000

-1025000

1194000

126000

129000

-0.01

184000

-0.01

2000

-771000

-890000

-0.10

-898000

-8000

289000

-0.10

9334000

455000

9334000

13883000 38000

27000

272000

-335000

1000

289000

8198000

-324000

264000

150000

5229000

-112000

24000

-68000

-37000

-104000

-69000

-68000 86000 871000 2285000 92000 2079000

32000

13000

8000

37000

310000

126000

184000

-14000

138000

8198000

180000

5229000

184000

5413000 272000

109000

10000

-0.19

477000

-0.19

-1835000

35000

5614000

-443000

-1000

761000

-443000

1844000

16205000

191000

7675000

-1835000

1958000

69000

211000

-0.05

213000

-0.05

5000

-1187000

-1392000

-0.15

-1393000

-1000

302000

-0.15

9443000

647000

9443000

16418000 140000

45000

151000

-549000

2000

246000

8509000

292000

186000

7545000

-638000

8000

3788000

-36000

-322000

3771000

-85000

17000 107000 1411000 3006000 35000 3199000

28000

16000

8000

36000

282000

69000

213000

530000

146000

8509000

1698000

7545000

213000

7758000 151000

71000

0000096793 us-gaap:ManagementMember 2016-01-01 2016-03-31 0000096793 ssy:OtherMemberMember 2016-01-01 2016-03-31 0000096793 ssy:HealthcareFacilitiesSegmentMember 2016-01-01 2016-03-31 0000096793 ssy:PharmacySegmentMember 2016-01-01 2016-03-31 0000096793 ssy:HealthcareFacilitiesSegmentMemberus-gaap:SegmentDiscontinuedOperationsMember 2016-01-01 2016-03-31 0000096793 us-gaap:SegmentDiscontinuedOperationsMember 2016-01-01 2016-03-31 0000096793 ssy:HealthcareFacilitiesSegmentMemberus-gaap:SegmentContinuingOperationsMember 2016-01-01 2016-03-31 0000096793 ssy:PharmacySegmentMemberus-gaap:SegmentContinuingOperationsMember 2016-01-01 2016-03-31 0000096793 us-gaap:SegmentContinuingOperationsMember 2016-01-01 2016-03-31 0000096793 ssy:LifeSciencesAndEngineeringSegmentMember 2016-01-01 2016-03-31 0000096793 ssy:MedicareMemberssy:HealthcareFacilitiesSegmentMember 2016-01-01 2016-03-31 0000096793 ssy:OtherHealthcareEntityMemberssy:HealthcareFacilitiesSegmentMember 2016-01-01 2016-03-31 0000096793 ssy:MedicaidMemberssy:HealthcareFacilitiesSegmentMember 2016-01-01 2016-03-31 0000096793 ssy:ManagedCareAndOtherInsurersMemberssy:HealthcareFacilitiesSegmentMember 2016-01-01 2016-03-31 0000096793 us-gaap:SelfPayMemberssy:HealthcareFacilitiesSegmentMember 2016-01-01 2016-03-31 0000096793 us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberssy:OtherSoldHospitalMember 2016-01-01 2016-03-31 0000096793 us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberssy:ChestateeHospitalMember 2016-01-01 2016-03-31 0000096793 us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberssy:LifeSciencesAndEngineeringSegmentMember 2016-01-01 2016-03-31 0000096793 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember 2016-01-01 2016-03-31 0000096793 us-gaap:OperatingSegmentsMemberssy:HealthcareFacilitiesSegmentMember 2016-01-01 2016-03-31 0000096793 us-gaap:OperatingSegmentsMemberssy:PharmacySegmentMember 2016-01-01 2016-03-31 0000096793 us-gaap:CorporateNonSegmentMember 2016-01-01 2016-03-31 0000096793 2016-01-01 2016-03-31 0000096793 2012-07-12 2014-12-31 0000096793 us-gaap:ManagementMember 2017-01-01 2017-03-31 0000096793 ssy:OtherMemberMember 2017-01-01 2017-03-31 0000096793 ssy:HealthcareFacilitiesSegmentMember 2017-01-01 2017-03-31 0000096793 ssy:PharmacySegmentMember 2017-01-01 2017-03-31 0000096793 ssy:HealthcareFacilitiesSegmentMemberus-gaap:SegmentDiscontinuedOperationsMember 2017-01-01 2017-03-31 0000096793 us-gaap:SegmentDiscontinuedOperationsMember 2017-01-01 2017-03-31 0000096793 ssy:HealthcareFacilitiesSegmentMemberus-gaap:SegmentContinuingOperationsMember 2017-01-01 2017-03-31 0000096793 ssy:PharmacySegmentMemberus-gaap:SegmentContinuingOperationsMember 2017-01-01 2017-03-31 0000096793 us-gaap:SegmentContinuingOperationsMember 2017-01-01 2017-03-31 0000096793 ssy:LifeSciencesAndEngineeringSegmentMember 2017-01-01 2017-03-31 0000096793 ssy:MedicareMemberssy:HealthcareFacilitiesSegmentMember 2017-01-01 2017-03-31 0000096793 ssy:OtherHealthcareEntityMemberssy:HealthcareFacilitiesSegmentMember 2017-01-01 2017-03-31 0000096793 ssy:MedicaidMemberssy:HealthcareFacilitiesSegmentMember 2017-01-01 2017-03-31 0000096793 ssy:ManagedCareAndOtherInsurersMemberssy:HealthcareFacilitiesSegmentMember 2017-01-01 2017-03-31 0000096793 us-gaap:SelfPayMemberssy:HealthcareFacilitiesSegmentMember 2017-01-01 2017-03-31 0000096793 us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberssy:OtherSoldHospitalMember 2017-01-01 2017-03-31 0000096793 us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberssy:ChestateeHospitalMember 2017-01-01 2017-03-31 0000096793 us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberssy:LifeSciencesAndEngineeringSegmentMember 2017-01-01 2017-03-31 0000096793 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember 2017-01-01 2017-03-31 0000096793 us-gaap:OperatingSegmentsMemberssy:HealthcareFacilitiesSegmentMember 2017-01-01 2017-03-31 0000096793 us-gaap:OperatingSegmentsMemberssy:PharmacySegmentMember 2017-01-01 2017-03-31 0000096793 us-gaap:CorporateNonSegmentMember 2017-01-01 2017-03-31 0000096793 2017-01-01 2017-03-31 0000096793 us-gaap:ManagementMember 2015-07-01 2016-03-31 0000096793 ssy:OtherMemberMember 2015-07-01 2016-03-31 0000096793 ssy:HealthcareFacilitiesSegmentMember 2015-07-01 2016-03-31 0000096793 ssy:PharmacySegmentMember 2015-07-01 2016-03-31 0000096793 ssy:HealthcareFacilitiesSegmentMemberus-gaap:SegmentDiscontinuedOperationsMember 2015-07-01 2016-03-31 0000096793 us-gaap:SegmentDiscontinuedOperationsMember 2015-07-01 2016-03-31 0000096793 ssy:HealthcareFacilitiesSegmentMemberus-gaap:SegmentContinuingOperationsMember 2015-07-01 2016-03-31 0000096793 ssy:PharmacySegmentMemberus-gaap:SegmentContinuingOperationsMember 2015-07-01 2016-03-31 0000096793 us-gaap:SegmentContinuingOperationsMember 2015-07-01 2016-03-31 0000096793 ssy:LifeSciencesAndEngineeringSegmentMember 2015-07-01 2016-03-31 0000096793 ssy:MedicareMemberssy:HealthcareFacilitiesSegmentMember 2015-07-01 2016-03-31 0000096793 ssy:OtherHealthcareEntityMemberssy:HealthcareFacilitiesSegmentMember 2015-07-01 2016-03-31 0000096793 ssy:MedicaidMemberssy:HealthcareFacilitiesSegmentMember 2015-07-01 2016-03-31 0000096793 ssy:ManagedCareAndOtherInsurersMemberssy:HealthcareFacilitiesSegmentMember 2015-07-01 2016-03-31 0000096793 us-gaap:SelfPayMemberssy:HealthcareFacilitiesSegmentMember 2015-07-01 2016-03-31 0000096793 ssy:TwoThousandFiveEquityIncentivePlansMember 2015-07-01 2016-03-31 0000096793 ssy:TwoThousandElevenDirectorStockOptionPlanMember 2015-07-01 2016-03-31 0000096793 us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberssy:OtherSoldHospitalMember 2015-07-01 2016-03-31 0000096793 us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberssy:ChestateeHospitalMember 2015-07-01 2016-03-31 0000096793 us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberssy:LifeSciencesAndEngineeringSegmentMember 2015-07-01 2016-03-31 0000096793 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember 2015-07-01 2016-03-31 0000096793 us-gaap:OperatingSegmentsMemberssy:HealthcareFacilitiesSegmentMember 2015-07-01 2016-03-31 0000096793 us-gaap:OperatingSegmentsMemberssy:PharmacySegmentMember 2015-07-01 2016-03-31 0000096793 us-gaap:CorporateNonSegmentMember 2015-07-01 2016-03-31 0000096793 2015-07-01 2016-03-31 0000096793 us-gaap:ManagementMember 2016-07-01 2017-03-31 0000096793 ssy:OtherMemberMember 2016-07-01 2017-03-31 0000096793 ssy:HealthcareFacilitiesSegmentMemberssy:FultonMissouriMember 2016-07-01 2017-03-31 0000096793 ssy:HealthcareFacilitiesSegmentMemberssy:DahlonegaGeorgiaMember 2016-07-01 2017-03-31 0000096793 ssy:HealthcareFacilitiesSegmentMember 2016-07-01 2017-03-31 0000096793 ssy:PharmacySegmentMember 2016-07-01 2017-03-31 0000096793 ssy:SpecialtyPharmacySegmentMembercountry:LA 2016-07-01 2017-03-31 0000096793 ssy:SpecialtyPharmacySegmentMember 2016-07-01 2017-03-31 0000096793 ssy:HealthcareFacilitiesSegmentMemberus-gaap:SegmentDiscontinuedOperationsMember 2016-07-01 2017-03-31 0000096793 us-gaap:SegmentDiscontinuedOperationsMember 2016-07-01 2017-03-31 0000096793 ssy:HealthcareFacilitiesSegmentMemberus-gaap:SegmentContinuingOperationsMember 2016-07-01 2017-03-31 0000096793 ssy:PharmacySegmentMemberus-gaap:SegmentContinuingOperationsMember 2016-07-01 2017-03-31 0000096793 us-gaap:SegmentContinuingOperationsMember 2016-07-01 2017-03-31 0000096793 ssy:LifeSciencesAndEngineeringSegmentMember 2016-07-01 2017-03-31 0000096793 ssy:MedicareMemberssy:HealthcareFacilitiesSegmentMember 2016-07-01 2017-03-31 0000096793 ssy:OtherHealthcareEntityMemberssy:HealthcareFacilitiesSegmentMember 2016-07-01 2017-03-31 0000096793 ssy:MedicaidMemberssy:HealthcareFacilitiesSegmentMember 2016-07-01 2017-03-31 0000096793 ssy:ManagedCareAndOtherInsurersMemberssy:HealthcareFacilitiesSegmentMember 2016-07-01 2017-03-31 0000096793 us-gaap:SelfPayMemberssy:HealthcareFacilitiesSegmentMember 2016-07-01 2017-03-31 0000096793 ssy:AcuteCareHospitalMemberssy:HealthcareFacilitiesSegmentMember 2016-07-01 2017-03-31 0000096793 ssy:TenderOfferMember 2016-07-01 2017-03-31 0000096793 ssy:TwoThousandElevenDirectorStockOptionPlanMember 2016-07-01 2017-03-31 0000096793 ssy:TenderOfferMemberus-gaap:MaximumMember 2016-07-01 2017-03-31 0000096793 us-gaap:SubsidiariesMemberssy:SunlinkHealthcareProfessionalPropertyRuralDevelopmentAuthorityMember 2016-07-01 2017-03-31 0000096793 ssy:SunlinkHealthcareProfessionalPropertyRuralDevelopmentAuthorityMember 2016-07-01 2017-03-31 0000096793 ssy:TraceRegionalHospitalRuralDevelopmentAuthorityLoanMemberus-gaap:MortgagesMember 2016-07-01 2017-03-31 0000096793 ssy:TraceRegionalHospitalRuralDevelopmentAuthorityLoanMember 2016-07-01 2017-03-31 0000096793 ssy:CarmichaelCashwayPharmacyNoteMember 2016-07-01 2017-03-31 0000096793 us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberssy:OtherSoldHospitalMember 2016-07-01 2017-03-31 0000096793 us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberssy:ChestateeHospitalMember 2016-07-01 2017-03-31 0000096793 us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberssy:LifeSciencesAndEngineeringSegmentMember 2016-07-01 2017-03-31 0000096793 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember 2016-07-01 2017-03-31 0000096793 us-gaap:OperatingSegmentsMemberssy:HealthcareFacilitiesSegmentMember 2016-07-01 2017-03-31 0000096793 us-gaap:OperatingSegmentsMemberssy:PharmacySegmentMember 2016-07-01 2017-03-31 0000096793 us-gaap:CorporateNonSegmentMember 2016-07-01 2017-03-31 0000096793 2016-07-01 2017-03-31 0000096793 ssy:SunlinkHealthcareProfessionalPropertyRuralDevelopmentAuthorityMember 2016-12-16 2016-12-16 0000096793 ssy:CarmichaelCashwayPharmacyNoteMember 2016-09-09 2016-09-09 0000096793 2016-11-07 2016-11-07 0000096793 ssy:ChestateeHospitalMemberssy:AssetPurchaseAgreementMember 2016-08-19 2016-08-19 0000096793 ssy:ChestateeHospitalMember 2016-08-19 2016-08-19 0000096793 us-gaap:RestatementAdjustmentMember 2016-06-30 0000096793 us-gaap:ScenarioPreviouslyReportedMember 2016-06-30 0000096793 us-gaap:ManagementMember 2016-06-30 0000096793 ssy:HealthcareFacilitiesSegmentMember 2016-06-30 0000096793 ssy:PharmacySegmentMember 2016-06-30 0000096793 ssy:MedicareLicenseMemberssy:PharmacySegmentMember 2016-06-30 0000096793 us-gaap:CustomerRelationshipsMemberssy:PharmacySegmentMember 2016-06-30 0000096793 us-gaap:TradeNamesMemberssy:PharmacySegmentMember 2016-06-30 0000096793 ssy:SunlinkHealthcareProfessionalPropertyRuralDevelopmentAuthorityMember 2016-06-30 0000096793 ssy:TraceRegionalHospitalRuralDevelopmentAuthorityLoanMember 2016-06-30 0000096793 ssy:CarmichaelCashwayPharmacyNoteMember 2016-06-30 0000096793 2016-06-30 0000096793 ssy:HealthcareFacilitiesSegmentMember 2015-06-30 0000096793 ssy:PharmacySegmentMember 2015-06-30 0000096793 2015-06-30 0000096793 ssy:TraceRegionalHospitalRuralDevelopmentAuthorityLoanMemberus-gaap:MortgagesMember 2012-07-11 0000096793 us-gaap:ManagementMember 2017-03-31 0000096793 ssy:HealthcareFacilitiesSegmentMember 2017-03-31 0000096793 ssy:PharmacySegmentMember 2017-03-31 0000096793 ssy:MedicareLicenseMemberssy:PharmacySegmentMember 2017-03-31 0000096793 us-gaap:CustomerRelationshipsMemberssy:PharmacySegmentMember 2017-03-31 0000096793 us-gaap:TradeNamesMemberssy:PharmacySegmentMember 2017-03-31 0000096793 ssy:TenderOfferMember 2017-03-31 0000096793 ssy:OperatingLeasesMember 2017-03-31 0000096793 ssy:InterestOnOutstandingDebtMember 2017-03-31 0000096793 us-gaap:LongTermDebtMember 2017-03-31 0000096793 ssy:SunlinkHealthcareProfessionalPropertyRuralDevelopmentAuthorityMember 2017-03-31 0000096793 ssy:TraceRegionalHospitalRuralDevelopmentAuthorityLoanMemberus-gaap:MinimumMember 2017-03-31 0000096793 ssy:TraceRegionalHospitalRuralDevelopmentAuthorityLoanMember 2017-03-31 0000096793 ssy:CarmichaelCashwayPharmacyNoteMember 2017-03-31 0000096793 us-gaap:OperatingSegmentsMemberssy:HealthcareFacilitiesSegmentMember 2017-03-31 0000096793 us-gaap:OperatingSegmentsMemberssy:PharmacySegmentMember 2017-03-31 0000096793 us-gaap:CorporateNonSegmentMember 2017-03-31 0000096793 2017-03-31 0000096793 ssy:HealthcareFacilitiesSegmentMember 2016-12-31 0000096793 ssy:PharmacySegmentMember 2016-12-31 0000096793 2016-12-31 0000096793 ssy:HealthcareFacilitiesSegmentMember 2016-03-31 0000096793 ssy:PharmacySegmentMember 2016-03-31 0000096793 us-gaap:OperatingSegmentsMemberssy:HealthcareFacilitiesSegmentMember 2016-03-31 0000096793 us-gaap:OperatingSegmentsMemberssy:PharmacySegmentMember 2016-03-31 0000096793 us-gaap:CorporateNonSegmentMember 2016-03-31 0000096793 2016-03-31 0000096793 ssy:HealthcareFacilitiesSegmentMember 2015-12-31 0000096793 ssy:PharmacySegmentMember 2015-12-31 0000096793 2015-12-31 0000096793 ssy:CarmichaelCashwayPharmacyNoteMember 2008-04-22 0000096793 ssy:SunlinkHealthcareProfessionalPropertyRuralDevelopmentAuthorityMember 2016-12-16 0000096793 2017-05-11 0000096793 ssy:CarmichaelCashwayPharmacyNoteMember 2016-02-16 0000096793 us-gaap:SubsidiariesMemberssy:SunlinkHealthcareProfessionalPropertyRuralDevelopmentAuthorityMember 2012-10-31 iso4217:USD shares pure iso4217:USD shares ssy:Segment ssy:Hospital ssy:Bed ssy:Areas ssy:Location utr:acre ssy:Law_Firm

EX-101.SCH 7 ssy-20170331.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 103 - Statement - Condensed Consolidated Balance Sheets link:calculationLink link:presentationLink link:definitionLink 104 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 105 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Earnings (Loss) (Unaudited) link:calculationLink link:presentationLink link:definitionLink 106 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:calculationLink link:presentationLink link:definitionLink 107 - Disclosure - Basis of Presentation link:calculationLink link:presentationLink link:definitionLink 108 - Disclosure - Business Operations link:calculationLink link:presentationLink link:definitionLink 109 - Disclosure - Discontinued Operations link:calculationLink link:presentationLink link:definitionLink 110 - Disclosure - Restricted Cash link:calculationLink link:presentationLink link:definitionLink 111 - Disclosure - Shareholders' Equity link:calculationLink link:presentationLink link:definitionLink 112 - Disclosure - Revenue Recognition and Accounts Receivables link:calculationLink link:presentationLink link:definitionLink 113 - Disclosure - Goodwill and Intangible Assets link:calculationLink link:presentationLink link:definitionLink 114 - Disclosure - Long-Term Debt link:calculationLink link:presentationLink link:definitionLink 115 - Disclosure - Income Taxes link:calculationLink link:presentationLink link:definitionLink 116 - Disclosure - Commitments and Contingencies link:calculationLink link:presentationLink link:definitionLink 117 - Disclosure - Related Party Transactions link:calculationLink link:presentationLink link:definitionLink 118 - Disclosure - Financial Information by Segment link:calculationLink link:presentationLink link:definitionLink 119 - Disclosure - Discontinued Operations (Tables) link:calculationLink link:presentationLink link:definitionLink 120 - Disclosure - Revenue Recognition and Accounts Receivables (Tables) link:calculationLink link:presentationLink link:definitionLink 121 - Disclosure - Goodwill and Intangible Assets (Tables) link:calculationLink link:presentationLink link:definitionLink 122 - Disclosure - Long-Term Debt (Tables) link:calculationLink link:presentationLink link:definitionLink 123 - Disclosure - Commitments and Contingencies (Tables) link:calculationLink link:presentationLink link:definitionLink 124 - Disclosure - Financial Information by Segment (Tables) link:calculationLink link:presentationLink link:definitionLink 125 - Disclosure - Business Operations - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 126 - Disclosure - Discontinued Operations - Schedule of Discontinued Operations (Detail) link:calculationLink link:presentationLink link:definitionLink 127 - Disclosure - Discontinued Operations - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 128 - Disclosure - Discontinued Operations - Components of Pension Expense (Detail) link:calculationLink link:presentationLink link:definitionLink 129 - Disclosure - Restricted Cash - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 130 - Disclosure - Shareholders' Equity - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 131 - Disclosure - Revenue Recognition and Accounts Receivables - Summary of Revenues (Detail) link:calculationLink link:presentationLink link:definitionLink 132 - Disclosure - Revenue Recognition and Accounts Receivables - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 133 - Disclosure - Revenue Recognition and Accounts Receivable - Summary Information for Accounts Receivable (Detail) link:calculationLink link:presentationLink link:definitionLink 134 - Disclosure - Revenue Recognition and Accounts Receivable - Summary of Allowance for Doubtful Accounts (Detail) link:calculationLink link:presentationLink link:definitionLink 135 - Disclosure - Goodwill and Intangible Assets - Goodwill (Detail) link:calculationLink link:presentationLink link:definitionLink 136 - Disclosure - Goodwill and Intangible Assets - Intangible Assets (Detail) link:calculationLink link:presentationLink link:definitionLink 137 - Disclosure - Goodwill and Intangible Assets - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 138 - Disclosure - Long-Term Debt - Summary of Long-Term Debt (Detail) link:calculationLink link:presentationLink link:definitionLink 139 - Disclosure - Long-Term Debt (Trace RDA Loan and Trace Working Capital Loan) - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 140 - Disclosure - Long-Term Debt (SHPP RDA Loan) - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 141 - Disclosure - Long-Term Debt (Carmichael Notes) - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 142 - Disclosure - Long-Term Debt - Summary of Line Items Impacted by the Adoption of ASU 2016-3 (Detail) link:calculationLink link:presentationLink link:definitionLink 143 - Disclosure - Income Taxes - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 144 - Disclosure - Commitments and Contingencies - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 145 - Disclosure - Commitments and Contingencies - Schedule of Contractual Obligations, Commitments and Contingencies (Detail) link:calculationLink link:presentationLink link:definitionLink 146 - Disclosure - Related Party Transactions - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 147 - Disclosure - Financial Information by Segment - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 148 - Disclosure - Financial Information by Segment - Segment Information (Detail) link:calculationLink link:presentationLink link:definitionLink 149 - Disclosure - Long-Term Debt - Summary of Long-Term Debt (Detail) (Alternate 1) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 8 ssy-20170331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 ssy-20170331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 ssy-20170331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Accounts Payable, Current Accounts payable Accounts Payable, Related Parties Amount payable to law firms Accounts Receivable, Gross, Current Accounts receivable (net of contractual allowances) Accrued interest forgiveness. Accrued Interest Forgiveness Accrued interest forgiven Accrued Liabilities, Current Due to third party payors Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Less accumulated depreciation Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive loss Acute care hospital. Acute Care Hospital [Member] Acute Care Hospital [Member] Additional Paid in Capital, Common Stock Additional paid-in capital Adjusted Earnings Before Interest Taxes Depreciation And Amortization And Other Non Cash Items [Abstract] Adjusted Earnings Before Interest Taxes Depreciation And Amortization And Other Non Cash Items [Abstract] Adjusted Earnings Before Interest Taxes Depreciation And Amortization And Other Non Cash Items [Abstract] Allocated Share-based Compensation Expense Share-based compensation, amount recognized Allowance for Doubtful Accounts Receivable, Current Ending balance Beginning balance Less allowance for doubtful accounts Allowance for Doubtful Accounts Receivable, Period Increase (Decrease) Additions recognized as a reduction to revenues Allowance for Doubtful Accounts Receivable, Write-offs Accounts written off, net of recoveries Allowance for doubtful accounts. Allowance For Doubtful Accounts [Table Text Block] Summary of Allowance for Doubtful Accounts Amendment Flag Amendment Flag Amortization of Intangible Assets Amortization expense Asset Purchase Agreement And Related License Agreement [Abstract] Asset Purchase Agreement And Related License Agreement [Abstract] Asset Purchase Agreement And Related License Agreement [Abstract] Asset purchase agreement. Asset Purchase Agreement [Member] Asset Purchase Agreement [Member] Assets Assets TOTAL ASSETS Total Assets Assets [Abstract] ASSETS Assets, Current Total current assets Total current assets Assets, Current [Abstract] Current Assets: Assets, Noncurrent [Abstract] Noncurrent Assets: Disposal Group, Including Discontinued Operation, Assets, Current Current assets held for sale Business And Organization [Line Items] Business And Organization [Line Items] Business And Organization [Line Items] Business And Organization [Table] Business And Organization [Table] Business And Organization [Table] Capital Lease Obligations Capital lease obligations and other Carmichael. Carmichael's Cashway Pharmacy, Note [Member] Carmichael Notes [Member] Cash and Cash Equivalents, at Carrying Value Cash and Cash Equivalents End of Period Cash and Cash Equivalents Beginning of Period Cash and cash equivalents Cash and Cash Equivalents, Period Increase (Decrease) Net increase (decrease) in Cash and Cash Equivalents Chestatee hospital. Chestatee Hospital [Member] Chestatee Hospital [Member] Commitment And Contingencies [Line Items] Commitment And Contingencies [Line Items] Commitment And Contingencies [Line Items] Commitment And Contingencies [Table] Commitment And Contingencies [Table] Commitment And Contingencies [Table] Commitment, Contingency And Related Party Transactions [Abstract] Commitment, Contingency And Related Party Transactions [Abstract] Commitment, Contingency And Related Party Transactions [Abstract] Commitments and Contingencies Commitment and Contingencies Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Common Stock, No Par Value Common shares, without par value Common Stock, Shares, Issued Common shares, issued Common Stock, Shares, Outstanding Common shares, outstanding Common Stock, Value, Issued Common Shares, without par value: Issued and outstanding, 9,163 shares at March 31, 2017 and 9,444 at June 30, 2016 Comprehensive Income (Loss), Net of Tax, Attributable to Parent Comprehensive Earnings (Loss) Consolidation Items [Axis] Consolidation Items [Axis] Consolidation Items [Domain] Consolidation Items [Domain] Contractual Obligation Contractual obligations, commitments and contingencies Contractual Obligation, Due after Fifth Year Payments due in 5+ years Contractual Obligation, Due in Fourth Year Payments due in 4 years Contractual Obligation, Due in Second Year Payments due in 2 years Contractual Obligation, Due in Third Year Payments due in 3 years Contractual Obligation, Fiscal Year Maturity Schedule [Table Text Block] Schedule of Contractual Obligations, Commitments and Contingencies Contractual Obligation, Future Minimum Payments Due, Remainder of Fiscal Year Payments due in 1 year Corporate, Non-Segment [Member] Corporate and Other [Member] Cost of Goods Sold Cost of goods sold Cost of Services Purchased services Costs and Expenses [Abstract] Costs and Expenses Current Federal Tax Expense (Benefit) Federal tax expense (benefit) Current Fiscal Year End Date Current Fiscal Year End Date Current State and Local Tax Expense (Benefit) State tax expense (benefit) Customer Relationships [Member] Customer Relationships [Member] Dahlonega Georgia. Dahlonega Georgia Member Dahlonega Georgia [Member] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Debt Instrument [Axis] Debt Instrument [Axis] Debt Instrument, Basis Spread on Variable Rate Floating rate of interest, spread Debt Instrument, Description of Variable Rate Basis Debt instrument description Debt Instrument, Face Amount Loan agreement amount Debt Instrument, Interest Rate, Effective Percentage Floating rate of interest equal to the greater of (i) the prime rate (as published in The Wall Street Journal) plus variable or (ii) stated Debt Instrument, Interest Rate, Stated Percentage Interest rate percentage Debt Instrument, Issuance Date Date of loan agreement Debt Instrument [Line Items] Debt Instrument [Line Items] Debt Instrument, Maturity Date Note due date Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Debt Instrument, Periodic Payment Principal and interest payment Debt Instrument, Periodic Payment, Principal Principal payment Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Debt Instrument, Term Debt instrument maturity period Debt pre payment penalty. Debt Pre Payment Penalty Early repayment penalty Deferred Tax Assets, Net of Valuation Allowance Net deferred tax assets Deferred Tax Assets, Net of Valuation Allowance, Current Deferred income tax asset Deferred Tax Assets, Net of Valuation Allowance, Noncurrent Deferred income tax asset Deferred Tax Assets, Valuation Allowance Deferred income tax valuation allowance Defined Benefit Plan, Amortization of Prior Service Cost (Credit) Amortization of prior service cost Defined Benefit Plan Disclosure [Line Items] Defined Benefit Plan Disclosure [Line Items] Defined Benefit Plan, Expected Return on Plan Assets Expected return on assets Defined Benefit Plan, Interest Cost Interest Cost Defined Benefit Plans, Estimated Future Employer Contributions in Current Fiscal Year Expected contribution to pension plan during the remaining fiscal year Deposit of restricted cash. Deposit Of Restricted Cash Deposit of restricted cash Depreciation, Depletion and Amortization, Nonproduction Depreciation and amortization Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Discontinued Operation, Gain (Loss) from Disposal of Discontinued Operation, before Income Tax Gain on Sale Discontinued operation income loss from discontinued operation before income tax. Discontinued Operation Income Loss From Discontinued Operation Before Income Tax [Abstract] Earnings (Loss) before income taxes: Discontinued Operation, Income (Loss) from Discontinued Operation During Phase-out Period, before Income Tax Earnings (Loss) before income taxes Discontinued Operation, Income (Loss) from Discontinued Operation During Phase-out Period, Net of Tax Earnings (Loss) from discontinued operations Earnings (Loss) from Discontinued Operations, net of tax Discontinued Operations and Disposal Groups [Abstract] Discontinued Operations and Disposal Groups [Abstract] Discontinued Operations, Disposed of by Sale [Member] Discontinued Operations, Disposed of by Sale [Member] Discontinued Operation, Tax Effect of Income (Loss) from Discontinued Operation During Phase-out Period Income tax expense (benefit) Disposal Group Classification [Axis] Disposal Group Classification [Axis] Disposal Group Classification [Domain] Disposal Group Classification [Domain] Disposal Group, Including Discontinued Operation, Assets, Noncurrent Noncurrent assets held for sale Disposal group including discontinued operation revenue net of expenses. Disposal Group Including Discontinued Operation Revenue Net Of Expenses Net revenues Disposal Groups, Including Discontinued Operations, Disclosure [Text Block] Discontinued Operations Disposal Group Name [Domain] Disposal Group Name [Domain] Document and entity information Document And Entity Information [Abstract] Document And Entity Information [Abstract] Document Fiscal Period Focus Document Fiscal Period Focus Document Fiscal Year Focus Document Fiscal Year Focus Document Period End Date Document Period End Date Document Type Document Type Earnings (loss) per share continuing operations. Earnings Loss Per Share Continuing Operations [Abstract] Continuing Operations: Earnings (loss) per share discontinued operations. Earnings Loss Per Share Discontinued Operations [Abstract] Discontinued Operations: Earnings Per Share [Abstract] Net Earnings (Loss): Earnings Per Share, Basic Basic Earnings Per Share, Diluted Diluted Employee-related Liabilities, Current Accrued payroll and related taxes Entity Central Index Key Entity Central Index Key Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Entity [Domain] Entity [Domain] Entity Filer Category Entity Filer Category Entity Registrant Name Entity Registrant Name Equity [Abstract] Equity [Abstract] Extinguishment of Debt, Amount Notes paid Extinguishment of Debt [Axis] Extinguishment of Debt [Axis] Extinguishment of Debt, Type [Domain] Extinguishment of Debt, Type [Domain] Revenue from Financial and Health Care Services Financial And Healthcare Services Revenue Net revenues Operating revenues (net of contractual allowances) Finite-Lived Intangible Assets, Accumulated Amortization Accumulated Amortization Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Gross Finite-Lived Intangible Assets, Gross Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Fulton Missouri. Fulton Missouri Member Fulton Missouri [Member] Gain (Loss) on Extinguishment of Debt Gain (loss) on extinguishment of debt Loss on extinguishment of debt - net Gain (Loss) on Disposition of Assets for Financial Service Operations Gain on sale of assets Goodwill Goodwill Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Text Block] Goodwill and Intangible Assets Goodwill [Line Items] Goodwill [Line Items] Healthcare facilities segment. Healthcare Facilities Segment [Member] Healthcare Facilities Segment [Member] Health Care Organization, Patient Service Revenue Provision for Bad Debts Less provision for bad debts of Healthcare Facilities Segment Provision for doubtful accounts Health Care Organization, Receivable and Revenue Disclosures [Line Items] Health Care Organization, Receivable and Revenue Disclosures [Line Items] Health Care Organization, Revenue Sources [Axis] Health Care Organization, Revenue Sources [Axis] Health Care Organization, Revenue Sources [Domain] Health Care Organization, Revenue Sources [Domain] Health Care Organizations [Abstract] Health Care Organizations [Abstract] Health care organization significant change in estimates. Health Care Organization Significant Change In Estimates Net revenues for settlements and filings of prior year Medicare cost reports Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Earnings (Loss) from Continuing Operations before income taxes Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Earnings (Loss) from Continuing Operations Income (Loss) from Continuing Operations, Per Basic Share Basic Income (Loss) from Continuing Operations, Per Diluted Share Diluted Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share Basic Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share Diluted Income Statement [Abstract] Income Statement [Abstract] Disposal Group Name [Axis] Disposal Group Name [Axis] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Disposal Groups, Including Discontinued Operations [Table] Disposal Groups, Including Discontinued Operations [Table] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Income Tax Disclosure [Text Block] Income Taxes Income Taxes Paid, Net Income taxes Income Tax Expense (Benefit) Income tax expense (benefit) Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets [Line Items] Indefinite-lived Intangible Assets [Line Items] Indefinite-Lived Intangible Assets (Excluding Goodwill) Indefinite-Lived Intangible Assets Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-lived Intangible Assets, Major Class Name [Domain] Intangible Assets, Gross (Excluding Goodwill) Finite and Indefinite-Lived Intangible Assets, Gross Intangible Assets, Net (Excluding Goodwill) Intangible assets - net Net Intangibles Interest bearing covenant deposit. Interest Bearing Covenant Deposit Interest bearing deposit under financial covenant Interest Expense Interest expense - net Interest On Outstanding Debt [Member] Interest On Outstanding Debt [Member] Interest on Outstanding Debt [Member] Interest Paid Interest Inventory, Net Inventory LAOS Louisiana [Member] Labor and Related Expense Salaries, wages and benefits Legal Entity [Axis] Legal Entity [Axis] Liabilities and Equity Total Liabilities and Shareholders' Equity TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY Liabilities and Equity [Abstract] LIABILITIES AND SHAREHOLDERS' EQUITY Liabilities, Current Total current liabilities Total current liabilities Liabilities, Current [Abstract] Current liabilities: Liabilities, Noncurrent Total long-term liabilities Total long-term liabilities Liabilities, Noncurrent [Abstract] Long-Term Liabilities Disposal Group, Including Discontinued Operation, Liabilities, Current Current liabilities held for sale Life sciences and engineering segment. Life Sciences And Engineering Segment [Member] Life Sciences and Engineering [Member] Line of Credit Facility, Covenant Terms Covenant terms Line of Credit Facility, Expiration Date Working capital expiration date Line of Credit Facility, Initiation Date Working Capital Loan Agreement, initiation date Loans Payable Indebtedness under the loan RDA Loan Long-term Debt Total Total Long-term Debt, Current Maturities Current maturities of long-term debt Less current maturities Long-term Debt [Member] Long-Term Debt [Member] Long-term Debt, Excluding Current Maturities Total Long-term debt, excluding current maturities, total Long-term debt Long-term debt, net of debt issuance costs Long-term Debt [Text Block] Long-Term Debt Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Long term obligations. Long Term Obligations [Text Block] Summary of Long-Term Debt Managed care and other insurers. Managed Care And Other Insurers [Member] Managed Care & Other Insurance [Member] Management [Member] Management [Member] Maximum [Member] Maximum [Member] Medicaid. Medicaid [Member] Medicaid [Member] Medicare license. Medicare License [Member] Medicare License [Member] EX-101.PRE 11 ssy-20170331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 12 g328223g0506075110528.jpg GRAPHIC begin 644 g328223g0506075110528.jpg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end XML 13 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Mar. 31, 2017	May 11, 2017
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2017
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	Q3
Trading Symbol	SSY
Entity Registrant Name	SUNLINK HEALTH SYSTEMS INC
Entity Central Index Key	0000096793
Current Fiscal Year End Date	--06-30
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		9,162,608

XML 14 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2017	Jun. 30, 2016
Current Assets:
Cash and cash equivalents	$ 11,237	$ 3,261
Restricted cash	1,000	0
Receivables - net	6,300	6,166
Inventory	2,171	2,612
Deferred income tax asset	0	624
Current assets held for sale	0	2,461
Prepaid expense and other assets	2,784	2,768
Total current assets	23,492	17,892
Property, plant and equipment, at cost	31,669	33,914
Less accumulated depreciation	20,986	20,920
Property, plant and equipment - net	10,683	12,994
Noncurrent Assets:
Intangible assets - net	2,589	2,695
Goodwill	461	461
Deferred income tax asset	0	1,698
Noncurrent assets held for sale	0	7,633
Other noncurrent assets	908	732
Total noncurrent assets	3,958	13,219
TOTAL ASSETS	38,133	44,105
Current liabilities:
Accounts payable	1,851	3,391
Current maturities of long-term debt	503	7,473
Accrued payroll and related taxes	2,398	2,872
Due to third party payors	630	1,883
Current liabilities held for sale	0	2,745
Other accrued expenses	1,258	1,687
Total current liabilities	6,640	20,051
Long-Term Liabilities
Long-term debt, net of debt issuance costs	6,327	2,979
Noncurrent liability for professional liability risks	879	1,161
Other noncurrent liabilities	283	425
Total long-term liabilities	7,489	4,565
Commitment and Contingencies
Shareholders' Equity
Preferred Shares, authorized and unissued, 2,000 shares	0	0
Common Shares, without par value: Issued and outstanding, 9,163 shares at March 31, 2017 and 9,444 at June 30, 2016	4,581	4,722
Additional paid-in capital	13,099	13,539
Retained earnings	6,744	1,648
Accumulated other comprehensive loss	(420)	(420)
Total Shareholders' Equity	24,004	19,489
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	$ 38,133	$ 44,105

XML 15 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2017	Jun. 30, 2016
Statement of Financial Position [Abstract]
Preferred shares, authorized	2,000,000	2,000,000
Preferred shares, unissued	2,000,000	2,000,000
Common shares, without par value
Common shares, issued	9,163,000	9,444,000
Common shares, outstanding	9,163,000	9,444,000

XML 16 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations and Comprehensive Earnings (Loss) (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2017	Mar. 31, 2016
Income Statement [Abstract]
Operating revenues (net of contractual allowances)	$ 13,883	$ 16,418	$ 41,321	$ 50,834
Less provision for bad debts of Healthcare Facilities Segment	184	213	321	1,461
Net revenues	13,699	16,205	41,000	49,373
Costs and Expenses
Cost of goods sold	5,523	5,614	15,592	15,582
Salaries, wages and benefits	5,872	7,675	17,476	23,918
Provision for bad debts of Specialty Pharmacy Segment	126	69	342	429
Supplies	455	647	1,373	2,486
Purchased services	692	761	2,113	2,510
Other operating expenses	1,194	1,958	4,015	6,125
Rent and lease expense	142	191	409	582
Depreciation and amortization	466	477	1,376	1,356
Operating Loss	(771)	(1,187)	(1,696)	(3,615)
Other Income, (Expense):
Gain on sale of assets	2	5	3,019	12
Loss on extinguishment of debt - net	0	0	(243)	0
Interest expense - net	(129)	(211)	(507)	(637)
Earnings (Loss) from Continuing Operations before income taxes	(898)	(1,393)	573	(4,240)
Income tax expense (benefit)	(8)	(1)	(236)	6,851
Earnings (Loss) from Continuing Operations	(890)	(1,392)	809	(11,091)
Earnings (Loss) from Discontinued Operations, net of tax	(135)	(443)	4,287	(1,758)
Net Earnings (Loss)	(1,025)	(1,835)	5,096	(12,849)
Other comprehensive income	0	0	0	0
Comprehensive Earnings (Loss)	$ (1,025)	$ (1,835)	$ 5,096	$ (12,849)
Continuing Operations:
Basic	$ (0.10)	$ (0.15)	$ 0.09	$ (1.17)
Diluted	(0.10)	(0.15)	0.09	(1.17)
Discontinued Operations:
Basic	(0.01)	(0.05)	0.46	(0.19)
Diluted	(0.01)	(0.05)	0.45	(0.19)
Net Earnings (Loss):
Basic	(0.11)	(0.19)	0.54	(1.36)
Diluted	$ (0.11)	$ (0.19)	$ 0.54	$ (1.36)
Weighted-Average Common Shares Outstanding:
Basic	9,334	9,443	9,408	9,443
Diluted	9,334	9,443	9,429	9,443

XML 17 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Statement of Cash Flows [Abstract]
Net Cash Used in Operating Activities	$ (4,999)	$ (291)
Cash Flows from Investing Activities:
Proceeds from sale of Chestatee	14,620	0
Proceeds from sale of medical office building and other assets	4,942	0
Expenditures for property, plant and equipment - continuing operations	(1,097)	(1,127)
Expenditures for property, plant and equipment - discontinued operations	0	(66)
Net Cash Provided by (Used in) Investing Activities	18,465	(1,193)
Cash Flows from Financing Activities:
Payments on long-term debt - continuing operation	(3,850)	(601)
Repurchase of common shares	(640)	0
Deposit of restricted cash	(1,000)	0
Net Cash Used in Financing Activities	(5,490)	(601)
Net increase (decrease) in Cash and Cash Equivalents	7,976	(2,085)
Cash and Cash Equivalents Beginning of Period	3,261	5,974
Cash and Cash Equivalents End of Period	11,237	3,889
Cash Paid for:
Interest	458	579
Income taxes	$ 141	$ 78

XML 18 R6.htm IDEA: XBRL DOCUMENT

Basis of Presentation	9 Months Ended
Basis of Presentation	Mar. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Note 1. –Basis of Presentation The accompanying unaudited Condensed Consolidated Financial Statements as of March 31, 2017 and for the three and nine month periods ended March 31, 2017 and 2016 have been prepared in accordance with Rule 10-01 of Regulation S-X of the Securities and Exchange Commission (“SEC”) and, as such, do not include all information required by accounting principles generally accepted in the United States of America (“GAAP”). The condensed consolidated June 30, 2016 balance sheet included in this interim filing has been derived from the audited financial statements at that date but does not include all of the information and related notes required by GAAP for complete financial statements. These Condensed Consolidated Financial Statements should be read in conjunction with the audited consolidated financial statements included in the SunLink Health Systems, Inc. (“SunLink”, “we”, “our”, “ours”, “us” or the “Company”) Annual Report on Form 10-K for the fiscal year ended June 30, 2016, filed with the SEC on September 30, 2016. In the opinion of management, the Condensed Consolidated Financial Statements, which are unaudited, include all adjustments, consisting only of normal recurring adjustments, necessary to present fairly the financial position and results of operations for the periods indicated. The results of operations for the three and nine month periods ended March 31, 2017 are not necessarily indicative of the results that may be expected for the entire fiscal year or any other interim period.

XML 19 R7.htm IDEA: XBRL DOCUMENT

Business Operations

9 Months Ended

Mar. 31, 2017

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Business Operations

Note 2. – Business Operations

Business Operations

SunLink owns businesses which are providers of healthcare services in certain non-urban markets in the United States. SunLink’s business is composed of the ownership of two business segments:

•

The Healthcare Facilities Segments, which is composed of:

•

A subsidiary which owns a closed hospital building and a medical office building in Clanton, Alabama, a portion of which is currently rented to an unaffiliated healthcare provider.

•

The Specialty Pharmacy Segment, which is composed of four operational areas:

•

Pharmacy products and services which are conducted in rural markets at three locations in Louisiana;

•

Specialty pharmacy services; and

•

Durable medical equipment consisting primarily of products for nursing homes and patient-administered home care.

XML 20 R8.htm IDEA: XBRL DOCUMENT

Discontinued Operations

9 Months Ended

Mar. 31, 2017

Discontinued Operations and Disposal Groups [Abstract]

Discontinued Operations

Note 3. – Discontinued Operations

Results for all of the businesses included in discontinued operations are presented in the following table:


	Three Months Ended						Nine Months Ended
	March 31,						March 31,
	2017			2016			2017			2016
Net Revenues:
Chestatee Hospital	$	—		$	3,771		$	2,369		$	11,357
Other Sold Hospitals		(68	)		17			(288	)		148

	$	(68	)	$	3,788		$	2,081		$	11,505

Earnings (Loss) before income taxes:
Chestatee Hospital	$	(104	)	$	(322	)	$	83		$	(1,432	)
Other Sold Hospitals		(69	)		(85	)		(304	)		(219	)
Life sciences and engineering		(37	)		(36	)		(112	)		(107	)
Gain on sale of Chestatee Hospital		0			0			7,270			0

Earnings (Loss) before income taxes		(210	)		(443	)		6,937			(1,758	)

Income tax expense (benefit)		(75	)		0			2,650			0

Earnings (Loss) from discontinued operations	$	(135	)	$	(443	)	$	4,287		$	(1,758	)

The components of pension expense for the three and nine months ended March 31, 2017 and 2016, respectively, were as follows:


	Three Months Ended						Nine Months Ended
	March 31,						March 31,
	2017			2016			2017			2016
Interest Cost	$	13		$	16		$	39		$	48
Expected return on assets		(8	)		(8	)		(24	)		(24	)
Amortization of prior service cost		32			28			97			83

Net pension expense	$	37		$	36		$	112		$	107

SunLink contributed $105 to the plan in the nine months ended March 31, 2017 and expects to contribute an additional $35 during the last quarter of the fiscal year ending June 30, 2017.

- Definition

The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=65878427&loc=SL51721533-107759

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721665-107760

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721675-107760

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=64862545&loc=SL51724579-110230

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721663-107760

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64862545&loc=d3e2941-110230

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=64827811&loc=d3e1361-107760

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721673-107760

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721659-107760

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5A
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721671-107760

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5D
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721677-107760

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64827811&loc=d3e1474-107760

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721683-107760

+ Details

XML 21 R9.htm IDEA: XBRL DOCUMENT

Restricted Cash	9 Months Ended
Restricted Cash	Mar. 31, 2017
Receivables [Abstract]
Restricted Cash	Note 4. – Restricted Cash Under an Fourth Amendment to the Trace RDA Loan (see Note 8. Long-Term Debt) a deposit of $1,000 into an interest bearing blocked account was made with the lender and certain financial covenants were modified. The deposit, which was made on January 13, 2017, will remain in the blocked account until compliance is achieved with respect to financial covenants in effect prior to the Amendment or until November 15, 2017, when the modified financial covenants will revert back to the pre-modification amounts. At March 31, 2017, Trace was in compliance with the modified covenants but not with the prior covenants.

XML 22 R10.htm IDEA: XBRL DOCUMENT

Shareholders' Equity	9 Months Ended
Shareholders' Equity	Mar. 31, 2017
Equity [Abstract]
Shareholders' Equity	Note 5. – Shareholders’ Equity *Common Share Purchase Tender Offer* – SunLink purchased 280,800 of its common shares at a price of $1.50 per share as a result of a tender offer (the “Offer”) which expired February 24, 2017. The aggregate purchase price of the common shares, including expenses of the Offer was $640. The Offer was subject to a number of terms and conditions described in the Offer to Purchase distributed to shareholders. *Charter Amendments to Protect Net Operating Losses* – On November 7, 2016, SunLink’s shareholders approved amendments to the Company’s article of incorporation to restrict certain transfers of common shares in order to protect future use of the Company’s federal and state income tax net operating losses. The amendments generally void transfers of shares that would result in the creation of a new 4.9% shareholder or result in an existing 4.9% shareholder acquiring additional shares. The purpose of the amendments is to assist the Company in protecting the value of its accumulated NOLs by limiting transfers of the Company’s common shares that could ultimately result in an “ownership change” under Section 382 of the Internal Revenue Code. The amendments to the Company’s articles of incorporation are designed to work in tandem with the Tax Benefits Preservation Rights Plan adopted by the company’s board of directors in September 2016. *Tax Benefits Protection Rights Plan* – On September 29, 2016, SunLink entered into a Tax Benefits Preservation Rights Plan (the “Tax Benefits Protection Rights Plan”). Effective September 29, 2016, the Board declared a dividend in the form of one preferred stock purchase right for each of the Company’s issued and outstanding common shares. The purpose of the Tax Benefits Protection Rights Plan is to diminish the risk that the Company’s ability to use its net operating losses and certain other tax assets to reduce potential future federal income tax obligations would become subject to limitations by reason of the Company experiencing an “ownership change,” as defined in Section 382 of the Code. *Stock-Based Compensation* For the three months ended March 31, 2017 and 2016, the Company recognized $5 and $10, respectively, in stock based compensation for options issued to employees and directors of the Company. For the nine months ended March 31, 2017 and 2016, the Company recognized $59 and $49, respectively, in stock based compensation for options issued to employees and directors of the Company. The fair value of the share options granted was estimated using the Black-Scholes option pricing model. There were 72,000 and 30,000 share options granted under the 2011 Director Stock Option Plan during the nine months ended March 31, 2017 and 2016, respectively. There were 45,000 share options granted under the 2005 Equity Incentive Plan during the nine months ended March 31, 2016.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74567-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

+ Details

XML 23 R11.htm IDEA: XBRL DOCUMENT

Revenue Recognition and Accounts Receivables

9 Months Ended

Mar. 31, 2017

Receivables [Abstract]

Revenue Recognition and Accounts Receivables

Note 6. – Revenue Recognition and Accounts Receivables

Revenues by payor were as follows for the three and nine months ended March 31, 2017 and 2016:


	Three Months Ended						Nine Months Ended
	March 31,						March 31,
	2017			2016			2017			2016
Healthcare Facilities Segment:
Medicare	$	2,079		$	3,199		$	6,447		$	9,202
Medicaid		2,285			3,006			7,185			9,235
Self-pay		86			107			356			1,231
Managed Care & Other Insurance		871			1,411			2,248			5,840
Other		92			35			374			102

Revenues before provision for doubtful accounts		5,413			7,758			16,610			25,610
Provision for doubtful accounts		(184	)		(213	)		(321	)		(1,461	)

Healthcare Facilities Segment Net Revenues		5,229			7,545			16,289			24,149
Pharmacy Segment Net Revenues		8,198			8,509			23,946			24,644
Other Revenues		272			151			765			580

Total Net Revenues	$	13,699		$	16,205		$	41,000		$	49,373

Summary information for accounts receivable is as follows:


	March 31			June 30,
	2017			2016
Accounts receivable (net of contractual allowances)	$	7,010		$	7,157
Less allowance for doubtful accounts		(710	)		(991	)

Patient accounts receivable - net	$	6,300		$	6,166


Three Months Ended March 31, 2017	Healthcare
	Facilities			Pharmacy			Total
Balance at January 1, 2017	$	332		$	400		$	732
Additions recognized as a reduction to revenues:
Continuing Operations		184			126			310
Discontinued Operations		(14	)		—			(14	)
Accounts written off, net of recoveries		(180	)		(138	)		(318	)

Balance at March 31, 2017	$	322		$	388		$	710


NIne Months Ended March 31, 2017	Healthcare
	Facilities			Pharmacy			Total
Balance at July 1, 2016	$	624		$	367		$	991
Additions recognized as a reduction to revenues:
Continuing Operations		321			342			663
Discontinued Operations		378			—			378
Accounts written off, net of recoveries		(1,001	)		(321	)		(1,322	)

Balance at March 31, 2017	$	322		$	388		$	710


Three Months Ended March 31, 2016	Healthcare
	Facilities			Pharmacy			Total
Balance at January 1, 2016	$	4,055		$	432		$	4,487
Additions recognized as a reduction to revenues:
Continuing Operations		213			69			282
Discontinued Operations		530			—			530
Accounts written off, net of recoveries		(1,698	)		(146	)		(1,844	)

Balance at March 31, 2016	$	3,100		$	355		$	3,455


Nine Months Ended March 31, 2016	Healthcare
	Facilities			Pharmacy			Total
Balance at July 1, 2015	$	4,962		$	385		$	5,347
Additions recognized as a reduction to revenues:
Continuing Operations		1,461			429			1,890
Discontinued Operations		2,116			—			2,116
Accounts written off, net of recoveries		(5,439	)		(459	)		(5,898	)

Balance at March 31, 2016	$	3,100		$	355		$	3,455

XML 24 R12.htm IDEA: XBRL DOCUMENT

Goodwill and Intangible Assets

9 Months Ended

Mar. 31, 2017

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Intangible Assets

Note 7. - Goodwill and Intangible Assets

SunLink’s goodwill and intangible assets are composed of:


	March 31,		June 30,
	2017		2016
Pharmacy Segment Goodwill	$	461	$	461

Intangibles consist of the following, net of amortization:


	March 31,			June 30,
	2017			2016
Pharmacy Segment Intangibles
Trade Name (non-amortizing)		2,000			2,000
Customer Relationships		1,089			1,089
Medicare License		769			769

		3,858			3,858
Accumulated Amortization		(1,269	)		(1,163	)

Net Intangibles	$	2,589		$	2,695

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details

XML 25 R13.htm IDEA: XBRL DOCUMENT

Long-Term Debt

9 Months Ended

Mar. 31, 2017

Debt Disclosure [Abstract]

Long-Term Debt

Note 8. –Long-Term Debt

Long-term debt consisted of the following:


	March 31,			June 30,
	2017			2016
Trace RDA Loan	$	7,321		$	7,698
SHPP RDA Loan		0			1,950
Carmichael Notes		0			1,508
Capital lease obligations and other		17			32

Total		7,338			11,188
Less unamortized debt issuance costs		(508	)		(736	)
Less current maturities		(503	)		(7,473	)

	$	6,327		$	2,979

The Trace RDA Loan contains various terms and conditions, including financial restrictions and limitations, and affirmative and negative covenants. The covenants include financial covenants measured on a quarterly basis which require Trace to comply with a ratio of current assets to current liabilities, debt service coverage, fixed charge ratio, and funded debt to EBITDA, all as defined in the Trace RDA Loan. At September 30, 2016 and June 30, 2016, Trace was not in compliance with the debt service coverage, fixed charge ratio and funded debt to EBITDA ratios. The Company received a waiver of these non-compliances from the lender for both measurement dates and the Trace RDA Loan was amended by the Fourth Amendment to Loan Agreement and Waiver dated January 6, 2017. Under the Fourth Amendment, the debt service coverage, the fixed charge coverage and funded debt to EBITDA ratios were amended for periods ended December 31, 2016, March 31, 2017 and June 30, 2017 and an additional covenant was entered into requiring the deposit of $1,000 into a blocked interest bearing account with the lender. The deposit, which was made on January 13, 2017, will remain in the blocked account until Trace achieves compliance with financial covenants in effect prior to the Amendment or November 15, 2017, when the modified financial covenants will revert back to the pre-modification amounts. At March 31, 2017, Trace was in compliance with the modified covenants but not with the prior covenants. Indebtedness of $7,698 as of June 30, 2016 is presented in current liabilities in the condensed consolidated balance sheet as a result of the financial covenant non-compliance at that date. The ability of Trace to continue to make the required debt service payments under the Trace RDA Loan depends on, among other things, its ability to generate sufficient cash flows, including from operating activities. If Trace is unable to generate sufficient cash flow from operations to meet debt service payments on the Trace RDA Loan, including in the event the lender were to declare an event of default and accelerate the maturity of the indebtedness, such failure could have material adverse effects on the Company. The Trace RDA Loan is guaranteed by the Company and one subsidiary.

The following is a summary of the line items impact of the adoption of ASU 2016-3 in the Company’s June 30, 2016 accompanying condensed consolidated balance sheet:


	As		Adjustments			As
	Originally		for the Adoption			Currently
	Reported		of ASU 2015-3			Reported
Prepaid expense and other current assets	$	2,777	$	(9	)	$	2,768
Total current assets	$	17,901	$	(9	)	$	17,892
Other noncurrent assets	$	1,459	$	(727	)	$	732
Total noncurrent assets	$	13,946	$	(727	)	$	13,219
Total Assets	$	44,841	$	(736	)	$	44,105
Current maturities of long-term debt	$	8,012	$	(539	)	$	7,473
Total current liabilities	$	20,590	$	(539	)	$	20,051
Long-term debt	$	3,176	$	(197	)	$	2,979
Total long-term liabilities	$	4,762	$	(197	)	$	4,565
Total Liabilities and Shareholders’ Equity	$	44,841	$	(736	)	$	44,105

XML 26 R14.htm IDEA: XBRL DOCUMENT

Income Taxes	9 Months Ended
Income Taxes	Mar. 31, 2017
Income Tax Disclosure [Abstract]
Income Taxes	Note 9. – Income Taxes Income tax benefit of $8 ($32 federal tax benefit and $24 state tax expense) and income tax benefit of $1 ($0 federal tax expense and $1 state tax benefit) was recorded for continuing operations for the three months ended March 31, 2017 and 2016, respectively. Income tax benefit of $236 ($221 federal tax benefit and $15 state tax benefit) and income tax expense of $6,851 ($6,210 federal tax expense and $641 state tax expense) was recorded for continuing operations for the nine months ended March 31, 2017 and 2016, respectively. In accordance with the Financial Accounting Standards Board Accounting Standards Codification (‘ASC”) 740, we evaluate our deferred taxes quarterly to determine if adjustments to our valuation allowance are required based on the consideration of available positive and negative evidence using a “more likely than not” standard with respect to whether deferred tax assets will be realized. Our evaluation considers, among other factors, our historical operating results, our expectation of future results of operations, the duration of applicable statuary carryforward periods and conditions of the healthcare industry. The ultimate realization of our deferred tax assets depends primarily on our ability to generate future taxable income during the periods in which the related temporary differences in the financial basis and the tax basis of the assets become deductible. The value of our deferred tax assets will depend on applicable income tax rates. At March 31, 2017, consistent with the above process, we evaluated the need for a valuation against our deferred tax assets and determined that it was more likely than not that none of our deferred tax assets would be realized. As a result, in accordance with ASC 740, we recognized a valuation allowance of $10,206 against the deferred tax asset so that there is no net long-term deferred income tax asset or liability at March 31, 2017. We conducted our evaluation by considering available positive and negative evidence to determine our ability to realize our deferred tax assets. In our evaluation, we gave more significant weight to evidence that was objective in nature as compared to subjective evidence. Also, more significant weight was given to evidence that directly related to our current financial performance as compared to less current evidence and future plans. The principal negative evidence that led us to determine at March 31, 2017 that all the deferred tax assets should have full valuation allowances was the three-year cumulative pre-tax loss from continuing operations as well as the underlying negative business conditions for rural healthcare businesses in which our Healthcare Facilities Segment businesses operate. For Federal income tax purposes, at March 31, 2017, the Company had approximately $11,100 of estimated net operating loss carry-forwards available for use in future years subject to the limitations of the provisions of Internal Revenue Code Section 382. The net operating loss carryforwards expire in 2024.

XML 27 R15.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

9 Months Ended

Mar. 31, 2017

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

Note 10. – Commitments and Contingencies

Contractual Obligations, Commitments and Contingencies


					Interest on
Payments	Long-Term		Operating		Outstanding
due in:	Debt		Leases		Debt
1 year	$	503	$	545	$	396
2 years		561		402		400
3 years		596		336		366
4 years		634		243		328
5+ years		5,044		59		803

	$	7,338	$	1,585	$	2,293

XML 28 R16.htm IDEA: XBRL DOCUMENT

Related Party Transactions	9 Months Ended
Related Party Transactions	Mar. 31, 2017
Related Party Transactions [Abstract]
Related Party Transactions	Note 11. - Related Party Transactions A director of the Company and the Company’s former corporate secretary are members of two different law firms, each of which provides services to SunLink. The Company has expensed an aggregate of $109 and $71 for legal services to these law firms in the three months ended March 31, 2017 and 2016, respectively. The Company has expensed an aggregate of $481 and $204 for legal services to these law firms in the nine months ended March 31, 2017 and 2016, respectively. Included in the Company’s condensed consolidated balance sheets at March 31, 2017 and June 30, 2016 is $21 and $75, respectively, of amounts payable to these law firms.

XML 29 R17.htm IDEA: XBRL DOCUMENT

Financial Information by Segment

9 Months Ended

Mar. 31, 2017

Segment Reporting [Abstract]

Financial Information by Segment

Note 12. - Financial Information by Segment

We evaluate performance of our operating segments based on revenue and operating profit (loss). At the beginning of the current fiscal year, the Company modified the approach to certain assets, and expense allocations to calculate segment assets, operating profit and depreciation and amortization. All prior year amounts have been changed to consistently apply the changed allocation method used in the current year. Segment information as of March 31, 2017 and 2016 and for the three and nine months then ended is as follows:


	Healthcare						Corporate
	Facilities			Pharmacy			and Other			Total
As of and for the three months ended March 31, 2017
Net revenues from external customers	$	5,229		$	8,198		$	272		$	13,699
Operating loss		(112	)		(324	)		(335	)		(771	)
Depreciation and amortization		150			289			27			466
Assets		12,458			11,519			14,156			38,133
Expenditures for property, plant and equipment		24			264			1			289

As of and for the three months ended March 31, 2016
Net revenues from external customers	$	7,545		$	8,509		$	151		$	16,205
Operating loss		(638	)		—			(549	)		(1,187	)
Depreciation and amortization		186			246			45			477
Assets		26,288			12,135			6,496			44,919
Expenditures for property, plant and equipment		8			292			2			302

As of and for the nine months ended March 31, 2017
Net revenues from external customers	$	16,289		$	23,946		$	765		$	41,000
Operating profit (loss)		443			(511	)		(1,628	)		(1,696	)
Depreciation and amortization		497			810			69			1,376
Assets		12,458			11,519			14,156			38,133
Expenditures for property, plant and equipment		246			739			112			1,097

As of and for the nine months ended March 31, 2016
Net revenues from external customers	$	24,149		$	24,644		$	580		$	49,373
Operating profit (loss)		(2,134	)		216			(1,697	)		(3,615	)
Depreciation and amortization		545			666			145			1,356
Assets		26,288			12,135			6,496			44,919
Expenditures for property, plant and equipment		93			1,031			3			1,127

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8906-108599

+ Details

XML 30 R18.htm IDEA: XBRL DOCUMENT

Discontinued Operations (Tables)

9 Months Ended

Mar. 31, 2017

Discontinued Operations and Disposal Groups [Abstract]

Schedule of Discontinued Operations

Results for all of the businesses included in discontinued operations are presented in the following table:


	Three Months Ended						Nine Months Ended
	March 31,						March 31,
	2017			2016			2017			2016
Net Revenues:
Chestatee Hospital	$	—		$	3,771		$	2,369		$	11,357
Other Sold Hospitals		(68	)		17			(288	)		148

	$	(68	)	$	3,788		$	2,081		$	11,505

Earnings (Loss) before income taxes:
Chestatee Hospital	$	(104	)	$	(322	)	$	83		$	(1,432	)
Other Sold Hospitals		(69	)		(85	)		(304	)		(219	)
Life sciences and engineering		(37	)		(36	)		(112	)		(107	)
Gain on sale of Chestatee Hospital		0			0			7,270			0

Earnings (Loss) before income taxes		(210	)		(443	)		6,937			(1,758	)

Income tax expense (benefit)		(75	)		0			2,650			0

Earnings (Loss) from discontinued operations	$	(135	)	$	(443	)	$	4,287		$	(1,758	)

Components of Pension Expense

The components of pension expense for the three and nine months ended March 31, 2017 and 2016, respectively, were as follows:


	Three Months Ended						Nine Months Ended
	March 31,						March 31,
	2017			2016			2017			2016
Interest Cost	$	13		$	16		$	39		$	48
Expected return on assets		(8	)		(8	)		(24	)		(24	)
Amortization of prior service cost		32			28			97			83

Net pension expense	$	37		$	36		$	112		$	107

- Definition

Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=65878427&loc=SL51721533-107759

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721665-107760

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64827811&loc=d3e1474-107760

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=64827811&loc=d3e1361-107760

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721683-107760

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=64862545&loc=SL51724579-110230

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721675-107760

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721663-107760

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64862545&loc=d3e2941-110230

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721673-107760

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721659-107760

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5A
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721671-107760

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5D
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721677-107760

+ Details

XML 31 R19.htm IDEA: XBRL DOCUMENT

Revenue Recognition and Accounts Receivables (Tables)

9 Months Ended

Mar. 31, 2017

Receivables [Abstract]

Summary of Revenues

Revenues by payor were as follows for the three and nine months ended March 31, 2017 and 2016:


	Three Months Ended						Nine Months Ended
	March 31,						March 31,
	2017			2016			2017			2016
Healthcare Facilities Segment:
Medicare	$	2,079		$	3,199		$	6,447		$	9,202
Medicaid		2,285			3,006			7,185			9,235
Self-pay		86			107			356			1,231
Managed Care & Other Insurance		871			1,411			2,248			5,840
Other		92			35			374			102

Revenues before provision for doubtful accounts		5,413			7,758			16,610			25,610
Provision for doubtful accounts		(184	)		(213	)		(321	)		(1,461	)

Healthcare Facilities Segment Net Revenues		5,229			7,545			16,289			24,149
Pharmacy Segment Net Revenues		8,198			8,509			23,946			24,644
Other Revenues		272			151			765			580

Total Net Revenues	$	13,699		$	16,205		$	41,000		$	49,373

Summary Information for Accounts Receivable

Summary information for accounts receivable is as follows:


	March 31			June 30,
	2017			2016
Accounts receivable (net of contractual allowances)	$	7,010		$	7,157
Less allowance for doubtful accounts		(710	)		(991	)

Patient accounts receivable - net	$	6,300		$	6,166

Summary of Allowance for Doubtful Accounts


Three Months Ended March 31, 2017	Healthcare
	Facilities			Pharmacy			Total
Balance at January 1, 2017	$	332		$	400		$	732
Additions recognized as a reduction to revenues:
Continuing Operations		184			126			310
Discontinued Operations		(14	)		—			(14	)
Accounts written off, net of recoveries		(180	)		(138	)		(318	)

Balance at March 31, 2017	$	322		$	388		$	710


NIne Months Ended March 31, 2017	Healthcare
	Facilities			Pharmacy			Total
Balance at July 1, 2016	$	624		$	367		$	991
Additions recognized as a reduction to revenues:
Continuing Operations		321			342			663
Discontinued Operations		378			—			378
Accounts written off, net of recoveries		(1,001	)		(321	)		(1,322	)

Balance at March 31, 2017	$	322		$	388		$	710


Three Months Ended March 31, 2016	Healthcare
	Facilities			Pharmacy			Total
Balance at January 1, 2016	$	4,055		$	432		$	4,487
Additions recognized as a reduction to revenues:
Continuing Operations		213			69			282
Discontinued Operations		530			—			530
Accounts written off, net of recoveries		(1,698	)		(146	)		(1,844	)

Balance at March 31, 2016	$	3,100		$	355		$	3,455


Nine Months Ended March 31, 2016	Healthcare
	Facilities			Pharmacy			Total
Balance at July 1, 2015	$	4,962		$	385		$	5,347
Additions recognized as a reduction to revenues:
Continuing Operations		1,461			429			1,890
Discontinued Operations		2,116			—			2,116
Accounts written off, net of recoveries		(5,439	)		(459	)		(5,898	)

Balance at March 31, 2016	$	3,100		$	355		$	3,455

XML 32 R20.htm IDEA: XBRL DOCUMENT

Goodwill and Intangible Assets (Tables)

9 Months Ended

Mar. 31, 2017

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill

SunLink’s goodwill and intangible assets are composed of:


	March 31,		June 30,
	2017		2016
Pharmacy Segment Goodwill	$	461	$	461

Intangible Assets

Intangibles consist of the following, net of amortization:


	March 31,			June 30,
	2017			2016
Pharmacy Segment Intangibles
Trade Name (non-amortizing)		2,000			2,000
Customer Relationships		1,089			1,089
Medicare License		769			769

		3,858			3,858
Accumulated Amortization		(1,269	)		(1,163	)

Net Intangibles	$	2,589		$	2,695

XML 33 R21.htm IDEA: XBRL DOCUMENT

Long-Term Debt (Tables)

9 Months Ended

Mar. 31, 2017

Debt Disclosure [Abstract]

Summary of Long-Term Debt

Long-term debt consisted of the following:


	March 31,			June 30,
	2017			2016
Trace RDA Loan	$	7,321		$	7,698
SHPP RDA Loan		0			1,950
Carmichael Notes		0			1,508
Capital lease obligations and other		17			32

Total		7,338			11,188
Less unamortized debt issuance costs		(508	)		(736	)
Less current maturities		(503	)		(7,473	)

	$	6,327		$	2,979

Summary of Line Items Impacted by the Adoption of ASU 2016-3

The following is a summary of the line items impact of the adoption of ASU 2016-3 in the Company’s June 30, 2016 accompanying condensed consolidated balance sheet:


	As		Adjustments			As
	Originally		for the Adoption			Currently
	Reported		of ASU 2015-3			Reported
Prepaid expense and other current assets	$	2,777	$	(9	)	$	2,768
Total current assets	$	17,901	$	(9	)	$	17,892
Other noncurrent assets	$	1,459	$	(727	)	$	732
Total noncurrent assets	$	13,946	$	(727	)	$	13,219
Total Assets	$	44,841	$	(736	)	$	44,105
Current maturities of long-term debt	$	8,012	$	(539	)	$	7,473
Total current liabilities	$	20,590	$	(539	)	$	20,051
Long-term debt	$	3,176	$	(197	)	$	2,979
Total long-term liabilities	$	4,762	$	(197	)	$	4,565
Total Liabilities and Shareholders’ Equity	$	44,841	$	(736	)	$	44,105

- Definition

Tabular disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64853466&loc=d3e22580-107794

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Direct Effects of a Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=66092750

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Indirect Effects of a Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=6515603

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=68064558&loc=d3e765-108305

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Accounting Change
-URI http://asc.fasb.org/extlink&oid=6503790

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=64853466&loc=d3e22499-107794

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.10-01.(b)(6))
-URI http://asc.fasb.org/extlink&oid=27015980&loc=d3e46468-122699

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64853466&loc=d3e22583-107794

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=6507316

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=68064558&loc=d3e725-108305

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Retrospective Application
-URI http://asc.fasb.org/extlink&oid=6523989

+ Details

XML 34 R22.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Tables)

9 Months Ended

Mar. 31, 2017

Commitments and Contingencies Disclosure [Abstract]

Schedule of Contractual Obligations, Commitments and Contingencies


					Interest on
Payments	Long-Term		Operating		Outstanding
due in:	Debt		Leases		Debt
1 year	$	503	$	545	$	396
2 years		561		402		400
3 years		596		336		366
4 years		634		243		328
5+ years		5,044		59		803

	$	7,338	$	1,585	$	2,293

XML 35 R23.htm IDEA: XBRL DOCUMENT

Financial Information by Segment (Tables)

9 Months Ended

Mar. 31, 2017

Segment Reporting [Abstract]

Segment Information


	Healthcare						Corporate
	Facilities			Pharmacy			and Other			Total
As of and for the three months ended March 31, 2017
Net revenues from external customers	$	5,229		$	8,198		$	272		$	13,699
Operating loss		(112	)		(324	)		(335	)		(771	)
Depreciation and amortization		150			289			27			466
Assets		12,458			11,519			14,156			38,133
Expenditures for property, plant and equipment		24			264			1			289

As of and for the three months ended March 31, 2016
Net revenues from external customers	$	7,545		$	8,509		$	151		$	16,205
Operating loss		(638	)		—			(549	)		(1,187	)
Depreciation and amortization		186			246			45			477
Assets		26,288			12,135			6,496			44,919
Expenditures for property, plant and equipment		8			292			2			302

As of and for the nine months ended March 31, 2017
Net revenues from external customers	$	16,289		$	23,946		$	765		$	41,000
Operating profit (loss)		443			(511	)		(1,628	)		(1,696	)
Depreciation and amortization		497			810			69			1,376
Assets		12,458			11,519			14,156			38,133
Expenditures for property, plant and equipment		246			739			112			1,097

As of and for the nine months ended March 31, 2016
Net revenues from external customers	$	24,149		$	24,644		$	580		$	49,373
Operating profit (loss)		(2,134	)		216			(1,697	)		(3,615	)
Depreciation and amortization		545			666			145			1,356
Assets		26,288			12,135			6,496			44,919
Expenditures for property, plant and equipment		93			1,031			3			1,127

XML 36 R24.htm IDEA: XBRL DOCUMENT

Business Operations - Additional Information (Detail)	9 Months Ended
Business Operations - Additional Information (Detail)	Mar. 31, 2017 a Segment Bed Areas Location
Business And Organization [Line Items]
Number of segments \| Segment	2
Specialty Pharmacy Segment [Member]
Business And Organization [Line Items]
Number of operational areas \| Areas	4
Healthcare Facilities Segment [Member]
Business And Organization [Line Items]
Number of bed in nursing home owned and operated by subsidiary	100
Healthcare Facilities Segment [Member] \| Acute Care Hospital [Member]
Business And Organization [Line Items]
Number of licensed-bed owned and operated by a subsidiary	84
Number of bed in geriatric psychiatry units owned and operated by subsidiary	18
Number of bed in nursing home owned and operated by subsidiary	66
Dahlonega Georgia [Member] \| Healthcare Facilities Segment [Member]
Business And Organization [Line Items]
Number of acres of unimproved land \| a	2
Fulton Missouri [Member] \| Healthcare Facilities Segment [Member]
Business And Organization [Line Items]
Number of acres of unimproved land \| a	12
Louisiana [Member] \| Specialty Pharmacy Segment [Member]
Business And Organization [Line Items]
Number of retail locations \| Location	3

XML 37 R25.htm IDEA: XBRL DOCUMENT

Discontinued Operations - Schedule of Discontinued Operations (Detail) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
	Aug. 19, 2016	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2017	Mar. 31, 2016
Earnings (Loss) before income taxes:
Earnings (Loss) before income taxes		$ (210)	$ (443)	$ 6,937	$ (1,758)
Income tax expense (benefit)		(75)	0	2,650	0
Earnings (Loss) from discontinued operations		(135)	(443)	4,287	(1,758)
Chestatee Hospital [Member]
Earnings (Loss) before income taxes:
Earnings (Loss) before income taxes	$ 7,270
Discontinued Operations, Disposed of by Sale [Member]
Net Revenues:
Net revenues		(68)	3,788	2,081	11,505
Discontinued Operations, Disposed of by Sale [Member] \| Chestatee Hospital [Member]
Net Revenues:
Net revenues			3,771	2,369	11,357
Earnings (Loss) before income taxes:
Gain on Sale		0	0	7,270	0
Earnings (Loss) before income taxes		(104)	(322)	83	(1,432)
Discontinued Operations, Disposed of by Sale [Member] \| Other Sold Hospitals [Member]
Net Revenues:
Net revenues		(68)	17	(288)	148
Earnings (Loss) before income taxes:
Earnings (Loss) before income taxes		(69)	(85)	(304)	(219)
Discontinued Operations, Disposed of by Sale [Member] \| Life Sciences and Engineering [Member]
Earnings (Loss) before income taxes:
Earnings (Loss) before income taxes		$ (37)	$ (36)	$ (112)	$ (107)

XML 38 R26.htm IDEA: XBRL DOCUMENT

Discontinued Operations - Additional Information (Detail) $ in Thousands		3 Months Ended		9 Months Ended		30 Months Ended
	Aug. 19, 2016 USD ($)	Mar. 31, 2017 USD ($)	Mar. 31, 2016 USD ($)	Mar. 31, 2017 USD ($)	Mar. 31, 2016 USD ($)	Dec. 31, 2014 Hospital
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from sale				$ 14,620	$ 0
Earnings (Loss) before income taxes		$ (210)	$ (443)	6,937	$ (1,758)
Number of Hospitals Sold \| Hospital						3
Chestatee Hospital [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Earnings (Loss) before income taxes	$ 7,270
Chestatee Hospital [Member] \| Asset Purchase Agreement [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from sale	$ 15,000
Life Sciences and Engineering [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Contribution to pension plan				105
Expected contribution to pension plan during the remaining fiscal year				$ 35

XML 39 R27.htm IDEA: XBRL DOCUMENT

Discontinued Operations - Components of Pension Expense (Detail) - Life Sciences and Engineering [Member] - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2017	Mar. 31, 2016
Defined Benefit Plan Disclosure [Line Items]
Interest Cost	$ 13	$ 16	$ 39	$ 48
Expected return on assets	(8)	(8)	(24)	(24)
Amortization of prior service cost	32	28	97	83
Net pension expense	$ 37	$ 36	$ 112	$ 107

XML 40 R28.htm IDEA: XBRL DOCUMENT

Restricted Cash - Additional Information (Detail) - USD ($) $ in Thousands	Mar. 31, 2017	Jun. 30, 2016
Restricted Cash and Cash Equivalents Items [Line Items]
Restricted cash	$ 1,000	$ 0
Trace RDA Loan [Member]
Restricted Cash and Cash Equivalents Items [Line Items]
Restricted cash	$ 1,000

XML 41 R29.htm IDEA: XBRL DOCUMENT

Shareholders' Equity - Additional Information (Detail) - USD ($)		3 Months Ended		9 Months Ended
	Nov. 07, 2016	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2017	Mar. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Repurchase of common shares				$ 640,000	$ 0
Shareholders threshold percentage	4.90%
Share-based compensation, amount recognized		$ 5,000	$ 10,000	$ 59,000	$ 49,000
2011 Director Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted				72,000	30,000
2005 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted					45,000
Tender Offer [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Repurchase of common shares				$ 640,000
Repurchase of common shares per share		$ 1.50		$ 1.50
Tender offer expiration period				Feb. 24, 2017
Tender Offer [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Repurchase of common shares				$ 280,800

XML 42 R30.htm IDEA: XBRL DOCUMENT

Revenue Recognition and Accounts Receivables - Summary of Revenues (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2017	Mar. 31, 2016
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Net revenues	$ 13,883	$ 16,418	$ 41,321	$ 50,834
Provision for doubtful accounts	(184)	(213)	(321)	(1,461)
Net revenues	13,699	16,205	41,000	49,373
Healthcare Facilities Segment [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Net revenues	5,413	7,758	16,610	25,610
Provision for doubtful accounts	(184)	(213)	(321)	(1,461)
Net revenues	5,229	7,545	16,289	24,149
Healthcare Facilities Segment [Member] \| Medicare [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Net revenues	2,079	3,199	6,447	9,202
Healthcare Facilities Segment [Member] \| Medicaid [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Net revenues	2,285	3,006	7,185	9,235
Healthcare Facilities Segment [Member] \| Self-Pay [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Net revenues	86	107	356	1,231
Healthcare Facilities Segment [Member] \| Managed Care & Other Insurance [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Net revenues	871	1,411	2,248	5,840
Healthcare Facilities Segment [Member] \| Other [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Net revenues	92	35	374	102
Pharmacy Segment [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Net revenues	8,198	8,509	23,946	24,644
Other Member [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Net revenues	$ 272	$ 151	$ 765	$ 580

XML 43 R31.htm IDEA: XBRL DOCUMENT

Revenue Recognition and Accounts Receivables - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2017	Mar. 31, 2016
Receivables [Abstract]
Net revenues for settlements and filings of prior year Medicare cost reports	$ 38	$ 140	$ 385	$ (662)

XML 44 R32.htm IDEA: XBRL DOCUMENT

Revenue Recognition and Accounts Receivable - Summary Information for Accounts Receivable (Detail) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Jun. 30, 2015
Receivables [Abstract]
Accounts receivable (net of contractual allowances)	$ 7,010		$ 7,157
Less allowance for doubtful accounts	(710)	$ (732)	(991)	$ (3,455)	$ (4,487)	$ (5,347)
Patient accounts receivable - net	$ 6,300		$ 6,166

XML 45 R33.htm IDEA: XBRL DOCUMENT

Revenue Recognition and Accounts Receivable - Summary of Allowance for Doubtful Accounts (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2017	Mar. 31, 2016
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Beginning balance	$ 732	$ 4,487	$ 991	$ 5,347
Accounts written off, net of recoveries	(318)	(1,844)	(1,322)	(5,898)
Ending balance	710	3,455	710	3,455
Continuing Operations [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Additions recognized as a reduction to revenues	310	282	663	1,890
Discontinued Operations [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Additions recognized as a reduction to revenues	(14)	530	378	2,116
Healthcare Facilities Segment [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Beginning balance	332	4,055	624	4,962
Accounts written off, net of recoveries	(180)	(1,698)	(1,001)	(5,439)
Ending balance	322	3,100	322	3,100
Healthcare Facilities Segment [Member] \| Continuing Operations [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Additions recognized as a reduction to revenues	184	213	321	1,461
Healthcare Facilities Segment [Member] \| Discontinued Operations [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Additions recognized as a reduction to revenues	(14)	530	378	2,116
Pharmacy Segment [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Beginning balance	400	432	367	385
Accounts written off, net of recoveries	(138)	(146)	(321)	(459)
Ending balance	388	355	388	355
Pharmacy Segment [Member] \| Continuing Operations [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Additions recognized as a reduction to revenues	$ 126	$ 69	$ 342	$ 429

XML 46 R34.htm IDEA: XBRL DOCUMENT

Goodwill and Intangible Assets - Goodwill (Detail) - USD ($) $ in Thousands	Mar. 31, 2017	Jun. 30, 2016
Goodwill [Line Items]
Goodwill	$ 461	$ 461
Pharmacy Segment [Member]
Goodwill [Line Items]
Goodwill	$ 461	$ 461

XML 47 R35.htm IDEA: XBRL DOCUMENT

Goodwill and Intangible Assets - Intangible Assets (Detail) - USD ($) $ in Thousands	Mar. 31, 2017	Jun. 30, 2016
Indefinite-lived Intangible Assets [Line Items]
Net Intangibles	$ 2,589	$ 2,695
Pharmacy Segment [Member]
Indefinite-lived Intangible Assets [Line Items]
Finite and Indefinite-Lived Intangible Assets, Gross	3,858	3,858
Accumulated Amortization	(1,269)	(1,163)
Net Intangibles	2,589	2,695
Trade Name [Member] \| Pharmacy Segment [Member]
Indefinite-lived Intangible Assets [Line Items]
Indefinite-Lived Intangible Assets	2,000	2,000
Customer Relationships [Member] \| Pharmacy Segment [Member]
Indefinite-lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	1,089	1,089
Medicare License [Member] \| Pharmacy Segment [Member]
Indefinite-lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	$ 769	$ 769

XML 48 R36.htm IDEA: XBRL DOCUMENT

Goodwill and Intangible Assets - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2017	Mar. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense	$ 35	$ 35	$ 106	$ 106

XML 49 R37.htm IDEA: XBRL DOCUMENT

Long-Term Debt - Summary of Long-Term Debt (Detail) - USD ($) $ in Thousands	Mar. 31, 2017	Jun. 30, 2016	Feb. 16, 2016
Debt Instrument [Line Items]
Capital lease obligations and other	$ 17	$ 32
Total	7,338	11,188
Total	7,338	11,188
Less unamortized debt issuance costs	(508)	(736)
Less current maturities	(503)	(7,473)
Total Long-term debt, excluding current maturities, total	6,327	2,979
Trace RDA Loan [Member]
Debt Instrument [Line Items]
RDA Loan	7,321	7,698
SHPP RDA Loan [Member]
Debt Instrument [Line Items]
RDA Loan	0	1,950
Carmichael Notes [Member]
Debt Instrument [Line Items]
Carmichael Notes	$ 0	$ 1,508	$ 1,255

XML 50 R38.htm IDEA: XBRL DOCUMENT

Long-Term Debt (Trace RDA Loan and Trace Working Capital Loan) - Additional Information (Detail) - Trace RDA Loan [Member] - USD ($) $ in Thousands	9 Months Ended
	Mar. 31, 2017	Jun. 30, 2016	Jul. 11, 2012
Debt Instrument [Line Items]
Working Capital Loan Agreement, initiation date	Jul. 05, 2012
Working capital expiration date	Jul. 02, 2016
Debt instrument maturity period	15 years
Floating rate of interest, spread	1.50%
Floating rate of interest equal to the greater of (i) the prime rate (as published in The Wall Street Journal) plus variable or (ii) stated	6.00%
Debt instrument description	Trace RDA Loan bears a floating rate of interest equal to the greater of (i) the prime rate (as published in The Wall Street Journal) plus 1.5%, or (ii) 6%
Indebtedness under the loan	$ 7,321	$ 7,698
Covenant terms	Under the Fourth Amendment, the debt service coverage, the fixed charge coverage and funded debt to EBITDA ratios were amended for periods ended December 31, 2016, March 31, 2017 and June 30, 2017 and an additional covenant was entered into requiring the deposit of $1,000 into a blocked interest bearing account with the lender. The deposit, which was made on January 13, 2017, will remain in the blocked account until Trace achieves compliance with financial covenants in effect prior to the Amendment or November 15, 2017
Interest bearing deposit under financial covenant	$ 1,000
Minimum [Member]
Debt Instrument [Line Items]
Floating rate of interest equal to the greater of (i) the prime rate (as published in The Wall Street Journal) plus variable or (ii) stated	6.00%
Mortgages [Member]
Debt Instrument [Line Items]
Date of loan agreement	Jul. 05, 2012
Loan agreement amount			$ 9,975

XML 51 R39.htm IDEA: XBRL DOCUMENT

Long-Term Debt (SHPP RDA Loan) - Additional Information (Detail) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
	Dec. 16, 2016	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2017	Mar. 31, 2016	Oct. 31, 2012
Debt Instrument [Line Items]
Gain (loss) on extinguishment of debt		$ 0	$ 0	$ (243)	$ 0
SHPP RDA Loan [Member]
Debt Instrument [Line Items]
Principal payment	$ 1,933
Early repayment penalty	97
Unamortized prepaid loan costs	$ 192
Gain (loss) on extinguishment of debt				$ (289)
SHPP RDA Loan [Member] \| Subsidiaries [Member]
Debt Instrument [Line Items]
Loan agreement amount						$ 2,100
Date of loan agreement				Oct. 31, 2012

XML 52 R40.htm IDEA: XBRL DOCUMENT

Long-Term Debt (Carmichael Notes) - Additional Information (Detail) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
	Sep. 09, 2016	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2017	Mar. 31, 2016	Jun. 30, 2016	Feb. 16, 2016	Apr. 22, 2008
Debt Instrument [Line Items]
Gain (loss) on extinguishment of debt		$ 0	$ 0	$ (243)	$ 0
Carmichael Notes [Member]
Debt Instrument [Line Items]
Loan agreement amount								$ 3,000
Interest rate percentage								8.00%
Date of loan agreement				Apr. 22, 2008
Principal and interest payment				$ 185
Carmichael Notes		$ 0		$ 0		$ 1,508	$ 1,255
Note due date				Oct. 22, 2017
Notes paid	$ 1,508
Accrued interest forgiven	$ 46
Gain (loss) on extinguishment of debt				$ 46

XML 53 R41.htm IDEA: XBRL DOCUMENT

Long-Term Debt - Summary of Line Items Impacted by the Adoption of ASU 2016-3 (Detail) - USD ($) $ in Thousands	Mar. 31, 2017	Jun. 30, 2016	Mar. 31, 2016
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Prepaid expense and other current assets	$ 2,784	$ 2,768
Total current assets	23,492	17,892
Other noncurrent assets	908	732
Total noncurrent assets	3,958	13,219
Total Assets	38,133	44,105	$ 44,919
Current maturities of long-term debt	503	7,473
Total current liabilities	6,640	20,051
Long-term debt	6,327	2,979
Total long-term liabilities	7,489	4,565
Total Liabilities and Shareholders' Equity	$ 38,133	44,105
As Originally Reported [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Prepaid expense and other current assets		2,777
Total current assets		17,901
Other noncurrent assets		1,459
Total noncurrent assets		13,946
Total Assets		44,841
Current maturities of long-term debt		8,012
Total current liabilities		20,590
Long-term debt		3,176
Total long-term liabilities		4,762
Total Liabilities and Shareholders' Equity		44,841
Adjustments for the Adoption of ASU 2015-3 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Prepaid expense and other current assets		(9)
Total current assets		(9)
Other noncurrent assets		(727)
Total noncurrent assets		(727)
Total Assets		(736)
Current maturities of long-term debt		(539)
Total current liabilities		(539)
Long-term debt		(197)
Total long-term liabilities		(197)
Total Liabilities and Shareholders' Equity		$ (736)

XML 54 R42.htm IDEA: XBRL DOCUMENT

Income Taxes - Additional Information (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2017	Mar. 31, 2016
Income Tax Disclosure [Abstract]
Income tax expense (benefit)	$ (8,000)	$ (1,000)	$ (236,000)	$ 6,851,000
Federal tax expense (benefit)	(32,000)	0	(221,000)	6,210,000
State tax expense (benefit)	24,000	$ (1,000)	(15,000)	$ 641,000
Deferred income tax valuation allowance	10,206,000		10,206,000
Net deferred tax assets	0		0
Net operating loss carry-forward	$ 11,100,000		$ 11,100,000
Net operating loss carryforward expiration year			2024

XML 55 R43.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies - Additional Information (Detail)	9 Months Ended
	Mar. 31, 2017 Hospital
Commitments and Contingencies Disclosure [Abstract]
Number of hospital facilities	4

XML 56 R44.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies - Schedule of Contractual Obligations, Commitments and Contingencies (Detail) $ in Thousands	Mar. 31, 2017 USD ($)
Long-Term Debt [Member]
Commitment And Contingencies [Line Items]
Payments due in 1 year	$ 503
Payments due in 2 years	561
Payments due in 3 years	596
Payments due in 4 years	634
Payments due in 5+ years	5,044
Contractual obligations, commitments and contingencies	7,338
Operating Leases [Member]
Commitment And Contingencies [Line Items]
Payments due in 1 year	545
Payments due in 2 years	402
Payments due in 3 years	336
Payments due in 4 years	243
Payments due in 5+ years	59
Contractual obligations, commitments and contingencies	1,585
Interest on Outstanding Debt [Member]
Commitment And Contingencies [Line Items]
Payments due in 1 year	396
Payments due in 2 years	400
Payments due in 3 years	366
Payments due in 4 years	328
Payments due in 5+ years	803
Contractual obligations, commitments and contingencies	$ 2,293

XML 57 R45.htm IDEA: XBRL DOCUMENT

Related Party Transactions - Additional Information (Detail) - Management [Member] $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2017 USD ($)	Mar. 31, 2016 USD ($)	Mar. 31, 2017 USD ($) Law_Firm	Mar. 31, 2016 USD ($)	Jun. 30, 2016 USD ($)
Related Party Transaction [Line Items]
Legal services to these law firms	$ 109	$ 71	$ 481	$ 204
Amount payable to law firms	$ 21		$ 21		$ 75
Number of law firms related to entities \| Law_Firm			2

XML 58 R46.htm IDEA: XBRL DOCUMENT

Financial Information by Segment - Additional Information (Detail)	9 Months Ended
	Mar. 31, 2017 Segment
Segment Reporting [Abstract]
Number of segments	2

XML 59 R47.htm IDEA: XBRL DOCUMENT

Financial Information by Segment - Segment Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2017	Mar. 31, 2016	Jun. 30, 2016
Segment Reporting Information [Line Items]
Net revenues from external customers	$ 13,699	$ 16,205	$ 41,000	$ 49,373
Operating profit (loss)	(771)	(1,187)	(1,696)	(3,615)
Depreciation and amortization	466	477	1,376	1,356
Assets	38,133	44,919	38,133	44,919	$ 44,105
Expenditures for property, plant and equipment	289	302	1,097	1,127
Healthcare Facilities Segment [Member]
Segment Reporting Information [Line Items]
Net revenues from external customers	5,229	7,545	16,289	24,149
Operating Segments [Member] \| Healthcare Facilities Segment [Member]
Segment Reporting Information [Line Items]
Net revenues from external customers	5,229	7,545	16,289	24,149
Operating profit (loss)	(112)	(638)	443	(2,134)
Depreciation and amortization	150	186	497	545
Assets	12,458	26,288	12,458	26,288
Expenditures for property, plant and equipment	24	8	246	93
Operating Segments [Member] \| Pharmacy Segment [Member]
Segment Reporting Information [Line Items]
Net revenues from external customers	8,198	8,509	23,946	24,644
Operating profit (loss)	(324)		(511)	216
Depreciation and amortization	289	246	810	666
Assets	11,519	12,135	11,519	12,135
Expenditures for property, plant and equipment	264	292	739	1,031
Corporate and Other [Member]
Segment Reporting Information [Line Items]
Net revenues from external customers	272	151	765	580
Operating profit (loss)	(335)	(549)	(1,628)	(1,697)
Depreciation and amortization	27	45	69	145
Assets	14,156	6,496	14,156	6,496
Expenditures for property, plant and equipment	$ 1	$ 2	$ 112	$ 3

EXCEL 60 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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end